

Shneider

Index

[More Information](#)

Index

- Aagenaes syndrome, 216
 AAP. *See* American Academy of Pediatrics
 ABCB4 gene, 27, 29. *See also* progressive familial intrahepatic cholestasis type 3
 ABCB11 gene, 26–7, 29. *See also* progressive familial intrahepatic cholestasis type 2
 ABCC2 gene, 27, 201
 ABCD1, 673–6
 ABCD2, 673–6
 ABCD3, 673–6
 ABCD3 deficiency, 604–5, 683–4
 ABCG5 gene, 27
 ABCG8 gene, 27, 267
 Abernethy malformation, 774
 abscess. *See* liver abscess
 ACAA1, 673–6
 ACAD9. *See* acyl-CoA dehydrogenase 9
 ACAD9 deletions, 640
 ACADs. *See* acyl-CoA dehydrogenases
 acalculous cholecystitis, 258
 clinical features, 258–9
 etiology and pathogenesis, 258
 ACBD5, 673–6
 acetaminophen hepatotoxicity
 in ALF, 38–9, 45
 clinical course, 355
 dose effects, 353–4
 innate detoxification defects, 357
 Kupffer cell in, 352–3
 mechanism of, 356
 in neonates, 357
 of new formulations, 357
 resistance in young children, 356–7
 therapeutic misadventure, 39, 355–6
 treatment, 38, 355, 372
 acetyl-CoA, 611
 acholic stools, 110, 157–8
 acid sphingomyelinase deficiency, 576–8
 ACOX1, 673–6
 ACOX1 deficiency. *See* acyl-CoA oxidase 1 deficiency
 ACOX2, 673–6
 ACOX2 deficiency. *See* acyl-CoA oxidase 2 deficiency
 ACOX3, 673–6
 actinomycosis, 717
 activated CD8⁺ T cell hepatitis, 38, 40
 active immunization
 HAV, 276–8
 HBV, 298
 HCV, 313
 acute intermittent porphyria (AIP), 530, 533
 activation of, 535
 clinical features of, 535–6
 diagnosis of, 536
 treatment of, 536–8
 acute liver crises, tyrosinemia, 564
 acute liver failure (ALF), 36
 clinical characterization, 36–7
 definition, 36, 37
 diagnostic approach, 43–4
 etiology, 37–8
 acetaminophen, 38–9
 drug or toxin, 38–40, 351, 372
 GALD, 40–1
 immune-mediated, 40
 indeterminate, 38
 infectious diseases, 42–3
 inherited metabolic disease, 41–2
 systemic conditions, 43
 in IAH, 323, 324, 329
 IEMs, 405–6
 immunologic disturbances in, 383–4
 liver histology in, 46–8, 49
 management
 cardiopulmonary complications, 52
 CNS complications, 48–50
 disease severity assessment, 52–3
 gastrointestinal complications, 51
 general principles, 48
 hematologic complications, 51
 infections, 52
 liver support, 52
 liver transplantation, 36–7, 53, 372, 804
 metabolic disorders, 51–2
 nutrition support, 52
 renal complications, 51
 natural history, 36–7
 outcomes, 36–7, 53
 pathogenesis, 45
 drug- and toxin-induced injury, 45
 hepatic immunology, 45
 inflammatory injury, 46
 liver cell regeneration, 46
 vascular injury, 45–6
 Wilson disease, 42, 491, 497, 500
 acute phase response, sepsis-associated cholestasis, 29–30
 acyclovir, 151
 acylcarnitine analysis, 412
 acyl-CoA dehydrogenase 9 (ACAD9), 615, 618
 acyl-CoA dehydrogenase deficiency, 412, 414
 acyl-CoA dehydrogenases (ACADs), 613–14
 long-chain, 614–15
 medium-chain, 615
 short-chain, 615
 very-long-chain, 614
 acyl-CoA oxidase 1 (ACOX1) deficiency, 684
 acyl-CoA oxidase 2 (ACOX2) deficiency, 684
 acyl-CoA oxidase deficiency, 604
 acylglycine profile, 412
 adalimumab, 364
 adaptive immune response, 45, 383. *See also* immunodeficiency
 adefovir dipivoxil, 153, 296
 adenoma. *See also* hepatocellular adenoma
 gallbladder, 260
 hepatic
 oral contraceptive use associated with, 362
 type IA glycogen storage diseases, 471
 adenomyomatosis, gallbladder, 260
 adenosine deaminase deficiency, 388
 adiponectin, in fetal hepatic metabolism, 13
 adolescents
 cholestasis in, 142–3
 PBD-ZSD in, 690
 ADP. *See* ALA-dehydratase deficient porphyria
 ADPKD. *See* autosomal dominant polycystic kidney disease
 adrenal disorders, 741
 Adriamycin, 358–9
 Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, 277–8
 AFP. *See* alpha-fetoprotein
 age, host, HBV infection course, 293
 AGL mutations, 473
 AGPS, 677
 AGXT, 677–8
 AhR. *See* aryl hydrocarbon receptor
 Aicardi-Goutière syndrome, 157
 AIH. *See* autoimmune hepatitis
 AIH-PSC overlap syndrome, 324, 326, 329, 333, 340, 341–2
 AIP. *See* acute intermittent porphyria
 AIRE mutations, 324–5
 AKR1D1 deficiency. *See* Δ^4 -3-oxosteroid 5 β -reductase deficiency
 ALA. *See* 5-aminolevulinic acid
 ALA-dehydratase, 531, 535
 ALA-dehydratase deficient porphyria (ADP), 533
 clinical features of, 535
 diagnosis of, 535
 frequency of, 535
 treatment of, 535
 Alagille syndrome (ALGS), 222, 238
 clinical features, 222, 223

- Alagille syndrome (cont.)
 cardiac, 225–6
 facial features, 229, 230
 growth retardation, 231, 237
 hepatic, 222–5
 neurodevelopment and
 quality of life, 231–2
 ocular, 229–31
 renal, 231
 skeletal, 227–9
 survival outcomes, 232
 vascular, 226–7
 diagnostic considerations,
 232–3, 234
 gallbladder hypoplasia in, 255
 genetics
 bile duct development, 235
 gene identification and
 mutation analysis, 234
 genetic testing, 235–6
 genotype–phenotype
 correlations, 235
JAGGED1, 222, 226, 233,
 234
NOTCH2, 222, 226, 233, 234
 Notch signaling pathway, 9,
 234–5
 hepatic tumors in, 224, 771,
 773
 histopathology, 224–5, 233
 management, 236–8
 liver transplantation, 224,
 227, 232, 237–8
 UDCA therapy, 120, 236
 alanine aminotransferase (ALT)
 cirrhosis, 65
 drug-induced liver disease,
 351
 in HBV infection, 287, 288,
 290–1, 294–5
 NAFLD/NASH, 654, 659, 660
 test description, 95–6
 Wilson disease, 494
 ALA-synthase, 531
 albumin
 cirrhosis, 65
 for HRS, 69
 in neonatal jaundice toxicity,
 193
 test description, 98
 alcaptonuria, 552
 ALDH3H2, 676
 ALDOB mutations, 463
 aldolase B, 462, 463. *See also*
 hereditary fructose
 intolerance
 aldose reductase inhibitors, for
 galactosemia, 460–1
 alemtuzumab, 395
 ALF. *See* acute liver
 failure
 ALGS. *See* Alagille syndrome
 alkaline phosphatase (AP)
 drug-induced liver disease,
 351
 in PSC, 336
 test description, 96–7
 Wilson disease, 494
- allogeneic stem cell
 transplantation, 736
 GVHD after, 738–9
 liver disease prior to, 736
 other hepatic complications,
 739
 VOD after
 compounds associated with,
 736, 737
 diagnosis, 737
 incidence, 737
 treatment of, 737–8
 allograft outflow, liver
 transplantation, 812
 appendost, 363
 Alpers syndrome
 laboratory diagnosis, 405–6
POLG deletions in, 634, 635–7
 valproic acid hepatotoxicity in,
 371–2
 alpha-fetoprotein (AFP)
 hepatic tumor diagnosis, 774,
 776
 tyrosinemia, 551, 554
 alpha-oxidation, peroxisome,
 674, 676
 alpha-tocopherol
 for cholestasis, 137–9
 for NAFLD/NASH, 666–7
 for Wilson disease, 503, 505
 ALT. *See* alanine
 aminotransferase
 aluminum
 for cholestasis, 141–2
 in IFALD pathogenesis, 249
 aluminum hydroxide antacids,
 119
 AMACR, 673–7
 AMACR deficiency. *See* α -
 methylacyl-CoA race-
 mase deficiency
 Amanita mushrooms, 39
 ambrisentan, 360
 amenorrhea
 cholestasis with, 142–3
 Wilson disease, 494
 American Academy of Pediatrics
 (AAP)
 breastfeeding
 recommendations for
 HBV infection, 289
 guidelines for
 hyperbilirubinemia
 management in neonate,
 189
 HAV vaccine
 recommendations, 277–8
 amino acid analysis, 703
 amino acid disorders
 laboratory diagnosis, 414–15
 newborn screening, 415
 amino acid metabolism
 in early development, 14–15
 peroxisome, 674, 677–8
 amino acids
 for cholestasis, 132
 in IFALD pathogenesis, 247
 plasma and urine, 102
- aminoacyl tRNA synthetase
 deficiency, 639–40
 5-aminolevulinic acid (ALA),
 530
 aminotransferases
 cirrhosis, 65
 test description, 95–6
 Wilson disease, 491, 494, 500
 amiodarone, 357–8
 ammonia
 blood, 702–3
 cerebral edema, 50
 in HE, 50, 70, 71
 LFTs based on, 100–1
 ammonium tetrathiomolybdate,
 for Wilson disease, 503,
 504–5
 amoebic abscess, 719–20
 amoxicillin-clavulanic acid, 367
 amphotericin, 365
 AMR. *See* antibody mediated
 rejection
 amylo-1,6-glucosidase
 deficiency, 467, 472–3
 biochemical and laboratory
 findings, 473
 biochemistry of glycogen
 metabolism, 467–8
 clinical presentation, 473
 molecular basis, 473
 treatment, 473–4
 amyloidosis, 743
 amylopectinosis. *See* glycogen
 storage disease, type IV
 ANAs. *See* anti-nuclear
 antibodies
 Andersen disease. *See* glycogen
 storage disease, type IV
 aneurysm, in Alagille syndrome,
 226–7
 angiography, portal
 hypertension, 83
 angiosarcomas, 780, 790
 angiotatin, 796
 anion exchange resins, for
 hyperlipidemia and
 xanthomas, 128
 antacids, 119
 anthropometrics,
 NAFLD/NASH
 diagnosis, 659–60
 antiarrhythmic agents, hepatic
 metabolism, 349
 antibody mediated rejection
 (AMR), 826
 anti-CD52 monoclonal
 antibodies, 395
 anticoagulation therapy,
 post-transplant, 817
 antifibrotic agents, for
 CF-associated liver
 disease, 452
 antifibrotic therapy, for cirrhosis,
 60
 anti-HBc, 286–7, 288
 anti-HBe, 286–7, 288
 anti-HBs, 286, 288
 antihistamines
 for Alagille syndrome,
 236
 for pruritus, 119
 anti-IL-2 receptor antagonists,
 395
 anti-liver–kidney microsomal
 antibody
 in AIH, 322
 in ALF, 40
 in drug-induced hepatitis,
 351–2
 anti-lymphocyte globulin, 394–5
 anti-neoplastic agents
 drug-induced liver disease,
 358–9, 736, 737
 for hepatic tumors, 795
 multidrug resistance to, 796
 anti-nuclear antibodies (ANAs)
 in AIH, 321, 322
 in ALF, 40
 antioxidant status, in CF, 442–3
 antioxidant therapy
 for ICT, 511
 mitochondrial hepatopathies,
 646, 647
 for NAFLD/NASH, 666–7
 for Wilson disease, 503, 505
 anti-platelet therapy, post-
 transplant, 817
 antiretroviral therapy (ART)
 hepatotoxicity, 642
 for HIV infection, 156
 anti-smooth muscle antibody
 (ASMA), in AIH, 321,
 322
 anti-soluble liver antigen/liver–
 pancreas antigen, in AIH,
 322
 anti-thymocyte globulin, 394–5
 α_1 -antitrypsin (α_1 -AT)
 biosynthesis, 422–4
 clearance and distribution, 424
 function, 422
 structure, 421–2, 423
 variants, 423
 α_1 -antitrypsin (α_1 -AT) deficiency
 in CF, 443
 clinical manifestations
 liver disease, 418–19, 420
 lung disease, 417–18,
 420–1
 diagnosis, 431
 laboratory diagnosis, 406
 neonatal cholestasis, 107
 pathophysiology
 cellular adaptive responses
 to mutant α_1 -antitrypsin
 Z, 425–8
 hepatic regeneration and
 carcinogenesis, 430–1
 liver injury pathogenesis,
 428–30
 mechanism for α_1 -AT
 deficiency in PiZZ
 individuals, 424–5, 426
 physiology
 biosynthesis of α_1 -AT,
 422–4

- clearance and distribution of α_1 -AT, 424
 function of α_1 -AT, 422
 structure of α_1 -AT, 421–2, 423
 variants of α_1 -AT, 423
 treatment, 431–3
 liver transplantation, 419, 431, 802–3
- antiviral therapy
 for HBV infection, 294, 295
 combination therapy, 297
 indications, 294–5
 interferons, 153, 295–6, 297
 nucleoside/nucleotide analogues, 153, 296–7
 for HCV infection
 DAAs, 153, 309–10, 311, 312
 ribavirin and interferon, 153, 310, 312
 for HEV infection, 281
- AP. *See* alkaline phosphatase
- APIS1* mutations, 511
- APC mutations, 770
- APECED syndrome, 324–5
- apical sodium-dependent bile acid transporter (ASBT)
 in bile formation and flow, 26–7, 28
 inhibitors
 for Alagille syndrome, 237
 for pruritus of cholestasis, 127
- aplastic anemia, 51
- APOC3* mutations, 657
- APOLT. *See* auxiliary partial orthotopic liver transplantation
- APRI score. *See* AST to platelet ratio index score
- AquaMEPHYTON, 139–40
- Aquasol A, 135–6
- arachidonic acid, for cholestasis, 132–3
- ARC syndrome. *See* arthrogryposis multiplex congenita, renal dysfunction, and cholestasis syndrome
- arginase deficiency, 701–2
- argininosuccinate lyase deficiency (ASLD), 701
- argininosuccinate synthase deficiency (ASSD), 701
- ARPKD. *See* autosomal recessive polycystic kidney disease
- arrhythmia, Wilson disease, 493–4
- ART. *See* antiretroviral therapy
- arthrogryposis multiplex congenita, renal dysfunction, and cholestasis (ARC) syndrome, 216–17
- aryl hydrocarbon receptor (AhR), 17
- ASAH gene, 578
- ASBT. *See* apical sodium-dependent bile acid transporter; ileal bile acid transporter
- ASC. *See* autoimmune sclerosing cholangitis
- Ascaris lumbricoides*, 264, 721
- ascites
 ALF complications and management, 51
 cirrhosis, 67–8
 portal hypertension, 74–5, 80, 82
 spontaneous bacterial peritonitis, 63, 68–9
- ascorbic acid, for NAFLD/NASH, 666–7
- asialoglycoprotein receptor antibody (ASGP-R), in AIH, 322
- ASLD. *See* argininosuccinate lyase deficiency
- ASMA. *See* anti-smooth muscle antibody
- aspartate aminotransferase (AST)
 cirrhosis, 65
 NAFLD/NASH, 659, 660
 test description, 95–6
 Wilson disease, 494
- aspergillosis, 727
- aspirin
 hepatotoxicity, 359
 post-transplant, 817
- ASSD. *See* argininosuccinate synthase deficiency
- AST. *See* aspartate aminotransferase
- AST to platelet ratio index (APRI) score, 449
- α_1 -AT. *See* α_1 -antitrypsin
- atomoxetine, 359–60
- ATOX1, 486
- ATP6VAP1-CDG, 478
- ATP6VAP2-CDG, 478
- ATP7A* mutations, 489
- ATP7B* mutations, 484, 485–6, 488, 489, 641
- ATP8B1* mutations. *See* progressive familial intrahepatic cholestasis type 1
- ATP synthesis, in mitochondria, 629–30
- atypical HAV, 275–6
- α_1 -ATZ, 417–18
 autophagy enhancer drugs for, 431–2
 cellular adaptive responses to, 425–8
 chemical chaperones for, 432–3
 gene therapy for, 432
 structure-based screening strategies for, 432
- autoantibodies
 in AIH, 321, 322
 in ALF, 40
 in PSC, 336
- autoimmune hepatitis (AIH), 330
 ALF in, 40
 autoantibodies and target autoantigens in, 321, 322
 diagnosis
 clinical features, 324, 326
 differential, 324–5
 scoring system, 323
 epidemiology, 321
 historical aspects, 321
 liver histology, 324, 326
 liver transplantation and, 330, 825–6
 management, 325–7
 AIH-PSC overlap syndrome treatment, 329
 budesonide, 328
 calcineurin inhibitors, 328–9
 liver failure treatment, 329
 mycophenolate mofetil, 328
 standard therapy, 327–8, 329
 outcomes and prognosis, 329–30
 pathogenesis, 321
 animal models, 323
 cellular immunity, 321–2
 genetic predisposition, 322–3
 humoral immunity in, 322
- autoimmune sclerosing cholangitis (ASC), 324, 326, 329, 333, 340, 341–2
- autoimmune-like hepatitis
 drug-induced, 324, 351–2
 in immunodeficiency, 388
- autophagy enhancer drugs, 431–2
- autosomal dominant polycystic kidney disease (ADPKD), 759–60
 pathogenesis and animal models, 762–5
- autosomal recessive polycystic kidney disease (ARPKD), 755–6, 757
- congenital hepatic fibrosis, 750, 751
 clinical manifestations, 752–4
 diagnosis, 754
 differential diagnosis, 754
 genetic counseling, 755
 imaging, 754
 laboratory findings, 754
 pathology, 750–2
 physical examination, 754
 surveillance, 755
 therapy, 755
- pathogenesis and animal models, 762–5
- autotaxin, 124
- auxiliary partial orthotopic liver transplantation (APOLT), 811
- Axenfeld anomaly, 229–30. *See also* Alagille syndrome
- azathioprine
 for AIH, 327–8
 hepatotoxicity, 360
 for post-liver transplant AIH, 330
 post-transplant, 817–18
- azithromycin
 hepatotoxicity, 361–2
 for HIV cholangiopathy, 389–90
- BAAT, 676–7
- BAAT deficiency. *See* bile acid-CoA:amino acid N-acyltransferase deficiency
- bacterial infections. *See also* Pediatric End-Stage Liver Disease
 in acalculous cholecystitis, 258
- actinomycosis, 717
- ALF in, 43
- borreliosis, 717–18
- brucellosis, 714–15
- cat scratch disease, 713–14
- cholangitis, 712–13
- cholestasis associated with, 29–30, 246, 730–1
- cirrhosis, 63, 68–9
- ehrlichiosis, 717
- gallbladder hydrops in, 257
- group A β -hemolytic streptococci, 715
- hyperbilirubinemia associated with, 710
- in IFALD pathogenesis, 246
- leptospirosis, 258, 718, 719
- listeriosis, 149, 715
- Mycobacterium avium* complex, 716–17
 HIV coinfection, 156
- sclerosing cholangitis, 386
- neonatal hepatitis, 147–9
 congenital syphilis, 149
 tuberculous hepatitis, 149
 urinary tract infections, 149
- neonatal jaundice, 192–3
- perihepatitis, 713
- post-transplant
 early, 820–1
 in long-term follow-up, 821
 patient evaluation, 821
 postoperative management, 816–17
- pyogenic liver abscess, 710–12
- Q fever, 718–19
- rickettsial disease, 258, 718
- spontaneous bacterial peritonitis, 63, 68–9
- syphilis, 149, 717
- toxic shock syndrome, 715
- in transferase-deficiency galactosemia, 457
- tuberculosis, 149, 715–16

Shneider

Index

[More In](#)

Index

- bacterial infections (cont.)
 typhoid hepatitis, 714
Yersinia enterocolitica, 715
- bacterial overgrowth, small
 bowel, 246
- BAL. *See* British Anti-Lewisite
- band ligation therapy, for
 portal hypertension, 84,
 86, 87–8
- Baraitser–Reardon syndrome,
 157
- bariatric surgery, for NAFLD/
 NASH, 667
- Bartonella henselae*, 713–14
- Bartter syndrome, 257
- basiliximab, 395
- BASM. *See* biliary atresia splenic
 malformation syndrome
- BCAAs. *See* branched-chain
 amino acids
- B-cells, hepatic immunology, 45
- BCS *L* deletions, 634, 639
- Beckwith–Wiedemann syndrome
 (BWS), 770, 771, 772
- Behçet disease, 740
- benign recurrent intrahepatic
 cholestasis (BRIC), 204
 clinical features, 204–6
 genetics, 207
 histopathology, 206–7
 laboratory findings, 206
 pathophysiology, 207–8
 treatment, 211–12
- beta-blockers
 hepatic metabolism, 349
 for portal hypertension, 84
- beta-hydroxybutyrate:
 acetoacetate
 (beta-OHB:AA) ratio,
 643–4
- beta-oxidation, peroxisome,
 673–6
- bezafibrate, 624
- bicarbonate umbrella, 27, 335
- bile
 cholesterol in, 264–6
 composition of, 26
 copper excretion in, 486–7
 flow of
 in early development, 20–1
 in enterohepatic circulation,
 26–7
 molecular determinants of,
 27, 28
 formation of, 26
 in early development, 21–3
 enterohepatic circulation,
 26–7
 molecular determinants of,
 27, 28
 physiological principles of,
 26
 malabsorption caused by
 reduced delivery of
 hepatic osteodystrophy, 130
 nutritional assessment,
 130
- nutritional management
 guidelines, 131
 nutritional therapy, 130–42
 steatorrhea, malnutrition,
 and growth failure,
 129–30
- retention of
 cholecystokinin therapy,
 122
 emerging pharmacologic
 approaches, 122–3
 fibrosis, 123
 glucocorticoid therapy,
 121–2
 hepatocellular injury, 118
 hepatocyte response, 27–9,
 30–1
 nuclear receptor agonist
 therapy, 122
 phenobarbital therapy, 121
 UDCA therapy, 118–21
- in systemic circulation, 123–4
 fatigue management, 127–8
 hyperlipidemia and
 xanthoma management,
 128–9
 pruritus management,
 124–7
- bile acid supplementation,
 peroxisomal disorders,
 689–90
- bile acid synthesis
 from cholesterol, 593–6
 conjugation, 596–7
 disorders influencing, 607–8
 during early life, 596
 importance of, 593
 metabolic pathways in, 593–6
 peroxisome pathways, 674,
 676–7
 regulation of, 597–8
 secondary, 597
- bile acid synthesis defects
 ABCD3 deficiency, 604–5,
 683–4
 acyl-CoA oxidase deficiency,
 604
 bile acid-CoA conjugation,
 606–7
 cholesterol 7 α -hydroxylase
 (CYP7A1) deficiency,
 598–600
 diagnosis and treatment of,
 607
 genetic defects and, 593, 594
 12 α -hydroxylase (CYP8B1)
 deficiency, 600–1
 3 β -hydroxy- Δ^5 C₂₇-steroid
 oxidoreductase
 (HSD3B7) deficiency,
 601–2
 laboratory diagnosis, 406
 metabolic liver disease with,
 598, 599
 2-methylacyl Co-A racemase
 (AMACR) deficiency,
 603–4
 neonatal hepatitis, 524, 526
- Δ^4 -3-oxosteroid 5 β -reductase
 (AKR1D1) deficiency,
 121, 524, 602
- oxysterol 7 α -hydroxylase
 (CYP7B1) deficiency,
 600
- peroxisomal disorders,
 605–6
- side-chain modification,
 602–3
- side-chain oxidation defect in
 25-hydroxylation
 pathway, 605
- steroid nucleus reaction, 598,
 600
- sterol 27-hydroxylase
 (CYP27A1) deficiency,
 603
- THCA-CoA oxidase
 deficiency, 604
- UDCA therapy, 121
- bile acid-binding agents:
 for hyperlipidemia and
 xanthomas in cholestasis,
 128
 for pruritus of cholestasis, 119,
 125, 236
- bile acid-CoA conjugation
 defects, 606–7
- bile acid-CoA:amino acid N-
 acyltransferase (BAAT)
 deficiency, 685
- bile acids
 in Alagille syndrome, 223
 in bile, 264–6
 blood concentrations, 19–20,
 28
 in CF, 442, 449
 conjugation of, 26–7
 in early development, 19–21
 enterohepatic circulation of,
 26–7
 hepatocyte retention of
 injury, 118
 response, 27–9, 30–1
 hydrophobic, hepatotoxicity,
 642
 intestinal absorption,
 19–20
 intracellular concentrations,
 28
 LFTs based on, 100
 metabolism, 19, 350–1
 peroxisome racemization of,
 674, 677
 secondary, 597
 secretion, 19, 20, 26, 27
 structure of, 593, 594
 synthesis, 19, 26
- bile duct
 development, 7
 morphogenesis, 7, 8
 Notch signaling, 9, 235
 TGF beta signaling, 8–9
 obstruction of, 268
 reconstruction, 812
 spontaneous perforation of,
 179
- bile duct cysts, 176. *See also*
 choledochal cysts
- bile duct paucity
 Alagille syndrome, 224, 233
 neonatal cholestasis, 109
- bile duct proliferation
 Alagille syndrome, 224–5,
 233
- biliary atresia, 169–70, 171–3,
 233
- bile salt export pump (BSEP –
 ABCB11)
 in bile formation and flow,
 26–7, 28
 in early development, 22
 phytosterol effects on, 247–9
- bile salt transport inhibitors, 127,
 237
- biliary atresia, 162–3
 Alagille syndrome differential
 diagnosis, 232–3, 234
 anatomic variants of, 171
 cause and pathogenesis, 164–5
 environmental toxic
 exposure, 167–8
 genetic factors, 166
 morphogenesis defect, 166
 pro-inflammatory
 mechanisms, 166–7
 vascular abnormalities, 168
 viral infection, 165
- cholestasis, 163
- chromosomal disorders,
 156–7
- clinical features, 163–4
- clinical forms, 163
- clinical presentation, 157–8
- cystic variant, 163
- diagnosis, 168
 approach to evaluation,
 168–9
 liver biopsy, 169–70
 surgical exploration, 170,
 172
- extrahepatic anomalies
 in, 163
- future research directions, 176
- incidence, 163
- liver transplantation for,
 174–5, 802, 811–12
 outcome, 175–6
 as primary therapy, 175
- neonatal cholestasis, 107, 110,
 112–14
- polysplenia and asplenia, 162,
 163
- portal hypertension, 81
- screening, 163–4
- situs inversus, 163, 166
- surgical management, 170
 anatomic variants, 171
 hepatopertoenterostomy
 (Kasai procedure), 170,
 171, 172, 175
 medical treatment
 after, 173
 outcome, 173–4
 prognosis after, 171–3

Shneider

Index

[More J](#)

Index

- reoperation after hepatoporo enterostomy, 173
sequence of, 170
UDCA therapy, 121
- biliary atresia splenic malformation syndrome (BASM), 163
- biliary colic, 260
- biliary cysts, 163
- biliary leaks, 825
- biliary microhamartomas, 760–1
- biliary sludge, 23, 263–4
- biliary stasis, 246, 265
- biliary strictures
after liver transplantation, 825
post-transplant, 821
- biliary tract disease
in CF, 445
neonatal cholestasis, 110
- bilirubin. *See also* serum bilirubin
LFTs based on, 99–100
measurement, 187
- bilirubin metabolism
conjugation, 185, 186, 350–1
decreased excretion
breastfeeding, 191–2, 195
drugs, 192
hepatic hypoperfusion and liver disease, 192
hormone dysfunctions, 192
increased bilirubin production with, 192–3
increased enterohepatic circulation, 191
Lucey–Driscoll syndrome, 192
maternal diabetes, 192
prematurity, 192
enterohepatic circulation, 184, 186, 187, 188
excretion of bilirubin
conjugates, 185–7
hepatocyte uptake, 183–5
increased production
decreased bilirubin excretion with, 192–3
extravascular blood, 191
isoimmunization, 189–91
labor induction with oxytocin, 191
polycythemia, 191
red blood cell abnormalities, 191
measurement of direct versus conjugated, 187
production and circulation, 182–3, 184
- bilirubin metabolism disorders, 182, 195
conjugated
hyperbilirubinemia, 197
Crigler–Najjar syndrome, 198–200, 357
Dubin–Johnson syndrome, 200–1, 406
Gilbert syndrome, 195–8
- Rotor syndrome, 200, 406
unconjugated
hyperbilirubinemia, 196
- biopsy, liver
acid sphingomyelinase deficiency, 576–7
AIH, 324, 326
Alagille syndrome, 224–5, 233
ALF, 46–8, 49
 α_1 -AT deficiency, 419, 420
biliary atresia, 169–70
CF-associated liver disease, 448–9
congenital infection
bacterial, 148
parasitic, 150
viral, 150, 151, 152, 153
donor liver, 810
drug-induced liver disease, 40
fibrosis, 60, 64–5
GALD-NH, 526
Gaucher disease, 575
glycogen storage diseases type IV, 474–5
HBV infection, 292
HCV infection, 308
hereditary hemochromatosis, 519
HIV infection, 156
ICC, 508
ICT, 510
IFALD, 243–4
 α -mannosidosis, 582
mitochondrial hepatopathies, 630, 631, 633–6, 646
NAFLD/NASH, 661–6
neonatal cholestasis, 112–13
Niemann–Pick disease type C, 580
PBD-ZSD, 680–2
PSC, 338–9
secondary iron overload, 522
tumor
cholangiocarcinoma, 779
errors in, 782
HB, 776–9, 781, 782, 784, 785, 786, 791
HCA, 776–7, 781–2
HCC, 776–7, 778–9, 786, 787
hemangioendotheliomas, 776–7
hemangiomas, 776–7
liquid, 796
mesenchymal hamartomas, 780–1, 792
MRT, 777–8
NSET, 779–80, 788
rhabdomyosarcoma, 777–8
valproic acid hepatotoxicity, 371
Wilson disease, 496, 497–9
- biotransformation
drug, 348–51
in early development, 16–19
birth, liver development at, 12
bis-choline tetrathiomolybdate, 501–2, 505
- black pigment stones, 261–3
chronic hemolytic disease, 263, 270
cirrhosis and chronic cholestasis, 264
miscellaneous, 264
TPN-related, 263–4
- blastemal pattern HB, 777, 782
- bleeding. *See* hemorrhage
- blood, extravascular, neonatal jaundice, 191
- blood ammonia, 702–3
- blood samples, IEM, 403, 413
- blue native polyacrylamide gel electrophoresis (BN-PAGE), mitochondrial hepatopathies, 645–6
- BMP. *See* bone morphogenetic protein
- BN-PAGE. *See* blue native polyacrylamide gel electrophoresis
- bone disease
Alagille syndrome with, 228
cholestasis with, 130
cirrhosis, 64
Wilson disease, 494
- bone marrow, in Gaucher disease, 574, 575
- bone mineral density, in cholestasis, 130
- bone morphogenetic protein (BMP), in hepatic specification, 3
induction signaling, 3–4
- booster doses, HBV vaccine, 299
- borreliosis
Borrelia recurrentis, 718
Lyme disease, 717–18
- bosentan, 360
- brain damage, galactose-induced, 459, 461
- brainstem auditory evoked potentials, in neonatal jaundice, 193
- branched-chain amino acids (BCAAs), for cholestasis, 132
- breakthrough infection, HBV, 299–300
- breastfeeding
for cholestasis, 132
HBV transmission, 289
neonatal jaundice, 191–2, 195
optimization of, 195
- BRIC. *See* benign recurrent intrahepatic cholestasis
- British Anti-Lewisite (BAL), for Wilson disease, 488
- bromosulphophthalein, 65–6
clearance in neonate, 20
- brown pigment stones, 261–3, 264
- brucellosis, 714–15
- BSEP. *See* bile salt export pump
- Budd–Chiari syndrome, 733–4
diagnostic evaluations, 83
- echinococcal disease, 720–1
oral contraceptive use associated with, 362
- budesonide
for AIH, 328
for PSC, 341–2
- bush teas, 363
- busulfan, 358–9
- butterfly vertebrae, Alagille syndrome, 227–9
- BWS. *See* Beckwith–Wiedemann syndrome
- Byler disease. *See* progressive familial intrahepatic cholestasis type 1
- C5b-9 complex deposition, 524
- C282Y *HFE* mutation, 516–18, 519, 520
- CADD5. *See* contiguous ABCD1 DXS1357E deletion syndrome
- caffeine
cirrhosis, 66
hepatic metabolism, 350
- calciferol. *See* vitamin D
- calcineurin inhibitors (CNIs)
for AIH, 328–9
for post-liver transplant AIH, 330
post-transplant, 817–18, 828
- calcitriol. *See* vitamin D
- calcium, for cholestasis, 140
- CALIPER. *See* Canadian Laboratory Initiative on Pediatric Reference Intervals
- caloric intake
cholestasis, 132
in NAFLD/NASH pathogenesis, 657
in PN, 247
- Campath-1 H, 395
- Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER), 94
- candidiasis, 725
- capillaritis, 722
- capillaries, portal hypertension, 74
- CAR. *See* constitutive androstane receptor
- carbamazepine
for α_1 -AT deficiency, 431–2
hepatotoxicity, 360–1
- carbamylphosphate synthetase (CPS) deficiency, 413–14
- carbohydrate, in PN, 247
- carbohydrate metabolism, 12–14. *See also* congenital disorders of glycosylation; fructose metabolism disorders; galactosemia; glycogen storage diseases
- carboplatin
drug-induced liver disease, 358–9
for hepatic tumors, 795

Shneider

Index

[More In](#)

Index

- carcinogenesis, in α_1 -AT deficiency, 430–1
- cardiac anomalies
in Alagille syndrome, 225–6
in biliary atresia, 163
liver disease associated with, 732–3
- cardiovascular manifestations
ALF, 52
cirrhosis, 62
tyrosinemia, 558, 560
Wilson disease, 493–4
- carmustine, 358–9
- carnitine
shuttle defects of, 617
transport defects, 617
in valproic acid hepatotoxicity, 372
- carnitine analysis, 412
- carnitine deficiency, 247
- carnitine palmitoyltransferase-IA deficiency, 617
- carnitine palmitoyltransferase-II deficiency, 617–18
- Caroli disease, 756–9
- Caroli syndrome, 756–9
- carvedilol, 84
- cat scratch disease, 713–14
- catalase (CAT), 678
- cataracts
galactosemia, 458–9, 461
Wilson disease, 490–1
- CCDC115-CDG, 478
- CCK-OP. *See* cholecystokinin-octapeptide
- CCS, in copper metabolism, 486
- CD. *See* Crohn disease
- CD40 L deficiency, 324–5
- CDG. *See* congenital disorders of glycosylation
- CEBP family, in intrahepatic bile duct development, 8–9
- CEBPA, in hepatocyte differentiation, 5
- ceftriaxone
gallbladder sludge development with, 264
neonatal jaundice with, 192
- celiac disease, 742
- cellular immunity, in
AIH, 321–2
- central nervous system (CNS)
ALF, 48–50
cirrhosis, 62–3, 70–1
neonatal jaundice, 193
- CEP. *See* congenital erythropoietic porphyria
- cerebral edema, ALF, 50
- cerebrotendinous xanthomatosis (CTX), 596, 602–3
- cerebrovascular anomalies,
Alagille syndrome, 226–7
- cereulide, 641
- ceruloplasmin, 486, 489, 494–5, 496
- CESD. *See* cholesteryl ester storage disease
- CF. *See* cystic fibrosis
- CFTR. *See* cystic fibrosis transmembrane conductance regulator
- chaparral leaf, 364
- checkpoint inhibitors, for HBV infection, 297
- chelation. *See also* copper chelation therapy
for secondary iron overload, 522, 523
- chemical chaperones, for α_1 -AT deficiency, 432–3
- chemoembolization, for hepatic tumors, 795–6
- chemotherapy
drug-induced liver disease, 358–9, 736, 737
for hepatic tumors, 795
multidrug resistance to, 796
- chenodeoxycholic acids
for cholesterol gallstones, 269
synthesis of, 593–6
- CHF. *See* congenital hepatic fibrosis
- Children's Hepatic Tumor International Collaboration (CHIC), 769, 796
tumor staging system, 775–6, 777, 778, 779
- Child-Turcotte-Pugh (CTP) scoring system, 805–6
- Chinese herbs, 363
- chloral hydrate, 192
- chloride channels. *See also* cystic fibrosis transmembrane conductance regulator
alternative to CFTR, 439, 451
- cholangiocarcinoma
in ABCB11, 209
constitutional genetic and metabolic abnormalities, 770–4
liver transplantation, 805
pathology, 779
in PSC, 339–40
- cholangiocyte channels. *See also* cystic fibrosis transmembrane conductance regulator
alternative to CFTR, 439, 451
- cholangiocytes
in cholestasis pathogenesis, 31
in ductal plate, 7, 8
hepatoblast differentiation into, 5–7
in PSC
bicarbonate umbrella hypothesis, 335
cholangiocyte senescence, 335
senescence, 335
- cholangiography, Alagille syndrome, 233
- cholangiopathy, HIV, 389–90
- cholangitic congenital hepatic fibrosis, 752–4
- cholangitis, bacterial, 712–13
- cholecalciferol, for cholestasis, 136–7
- cholecystectomy, 269, 270
- cholecystitis
acalculous, 258–9
acute, 268, 269–70
chronic, 268–70
treatment, 269–70
- cholecystokinin therapy, for cholestasis, 122
- cholecystokinin-octapeptide (CCK-OP), for IFALD, 251–2
- choledochal cysts, 162, 176–7
classification, 176
clinical features, 177
complications and outcome, 179
diagnosis, 177–8
malignancy in, 179
neonatal cholestasis, 110
pathogenesis, 177
spontaneous perforation of common bile duct, 179
treatment, 178–9
- cholelithiasis. *See also* gallstones
chronic, 268–9
IFALD, 243
treatment, 269–70
Wilson disease, 492
- choleric agents. *See also* urso-deoxycholic acid
for bile retention in cholestasis, 118
- cholestasis. *See also* familial hepatocellular cholestasis; neonatal cholestasis
adaptation to, 30–1
Alagille syndrome, 222–4, 236–8
bile retention in
cholecystokinin therapy, 122
emerging pharmacologic approaches, 122–3
fibrosis, 123
glucocorticoid therapy, 121–2
hepatocellular injury, 118
hepatocyte response, 27–9, 30–1
nuclear receptor agonist therapy, 122
phenobarbital therapy, 121
UDCA therapy, 118–21
biliary atresia, 163
black pigment gallstones in, 264
causes, 108
coagulopathy (vitamin K deficiency), 84–5, 98–9, 109–10, 139–40, 163–4, 204–6, 209, 223
- cholestasis, bacterial, 712–13
- cholecalciferol, for cholestasis, 136–7
- cholecystectomy, 269, 270
- cholecystitis
acalculous, 258–9
acute, 268, 269–70
chronic, 268–70
treatment, 269–70
- cholecystokinin therapy, for cholestasis, 122
- cholecystokinin-octapeptide (CCK-OP), for IFALD, 251–2
- choledochal cysts, 162, 176–7
classification, 176
clinical features, 177
complications and outcome, 179
diagnosis, 177–8
malignancy in, 179
neonatal cholestasis, 110
pathogenesis, 177
spontaneous perforation of common bile duct, 179
treatment, 178–9
- cholelithiasis. *See also* gallstones
chronic, 268–9
IFALD, 243
treatment, 269–70
Wilson disease, 492
- choleric agents. *See also* urso-deoxycholic acid
for bile retention in cholestasis, 118
- cholestasis. *See also* familial hepatocellular cholestasis; neonatal cholestasis
adaptation to, 30–1
Alagille syndrome, 222–4, 236–8
bile retention in
cholecystokinin therapy, 122
emerging pharmacologic approaches, 122–3
fibrosis, 123
glucocorticoid therapy, 121–2
hepatocellular injury, 118
hepatocyte response, 27–9, 30–1
nuclear receptor agonist therapy, 122
phenobarbital therapy, 121
UDCA therapy, 118–21
biliary atresia, 163
black pigment gallstones in, 264
causes, 108
coagulopathy (vitamin K deficiency), 84–5, 98–9, 109–10, 139–40, 163–4, 204–6, 209, 223
- copper accumulation
in, 512
definition, 27–8
enzymes detecting
AP, 96–7
GGT, 97
LAP, 98
5'NT, 97
extrahepatic, 107, 157–8
genetics, 108, 109, 113
growth failure in, 129–30, 142–3
IEMs, laboratory diagnosis, 406
IFALD, 242–4
intrahepatic, 107, 157–8
management, 116–18, 143–4
dental hygiene, 143
family support, 143
general pediatric care, 142
growth and development, 142–3
immunizations, 143
liver transplantation, 116, 802
medical treatment options, 119, 236
for reduced delivery of bile to intestine, 129–42
for retention of bile, 118–23
stage-based approach, 116, 118
for transfer of bile constituents into systemic circulation, 123–9
treatable causes, 117
mitochondrial dysfunction in, 642
nutritional therapy, 116, 130–2
assessment, 130
calcium and phosphate, 140
copper, manganese, and aluminum, 141–2
EFAs, 132–3
energy, 132
fat, 132
fat-soluble vitamins, 133–40
iron, 141
magnesium, 140–1
management guidelines, 131
protein, 132
selenium, 141
water-soluble vitamins, 140
zinc, 141
pathogenesis, 26
acquired mechanisms, 29
adaptation mechanisms, 30–1
drug-induced, 30, 351, 352
future research directions, 31–2
general principals, 27–9
genetic underpinnings, 29
sepsis-associated, 29–30, 246, 730–1
TPN-associated, 30

Shneider

Index

[More J](#)

Index

- pruritus of, 124
 pathogenesis, 124–5
 treatment, 125–7, 236
- rickets (vitamin D deficiency), 130, 136–7
- TPN-associated, 242, 243–4
 fatty acid role in, 247–9
 pathogenesis, 30
 UDCA therapy, 121
- cholesterol
 in Alagille syndrome, 223–4
 in bile, 264–6
 in cholestasis, 128–9
 in early development, 15
 in NAFLD/NASH
 pathogenesis, 656
 secretion of, 27
- cholesterol 7 α -hydroxylase (CYP7A1) deficiency, 598–600
- cholesterol gallstones, 261–2, 264–6
 cystic fibrosis, 266–7
 familial hypobetali
 ipoproteinemia, 267
 genetic predisposition to, 267
 ileal resection, jejunoileal bypass, or ileal Crohn disease, 266
 obesity, 266
 pregnancy, 267
 treatment, 269–70
- cholesterol synthesis-blocking agents, for
 hyperlipidemia and xanthomas, 129
- cholesterolosis, gallbladder, 260–1
- cholesteryl ester storage disease (CESD), 586–7
- cholestyramine
 for cholestasis, 119
 for hyperlipidemia and xanthomas in cholestasis, 128
 for pruritus of cholestasis, 125, 236
- choline deficiency, 247
- chromium, in IFALD
 pathogenesis, 249
- chromosomal disorders, neonatal hepatitis, 156–7
- chronic granulomatous disease, 394
- chronic hemolytic disease, black pigment gallstones in, 263, 270
- chronic liver disease, 58. *See also* cirrhosis; nonalcoholic fatty liver disease
 fibrosis in, 60
 immunologic disturbances in, 383–4
 malnutrition in, 71–2
 spontaneous bacterial peritonitis in, 63, 68–9
 tyrosinemia, 553, 559
- chronic progressive external ophthalmoplegia (CPEO), 635
- Chuen-Lin, 192
- cidofovir, 150
- ciliopathies, fibrocystic liver disease as, 749
- circulation, bile constituent transfer into, 123–4
 fatigue management, 127–8
 hyperlipidemia and xanthoma management, 128–9
 pruritus management, 124–7
- cirrhosis, 72. *See also* Indian Childhood Cirrhosis
 Alagille syndrome, 224–5
 α_1 -AT deficiency, 418
 black pigment gallstones in, 264
 in CF, 444–5, 449–50
 classifications, 58–9
 clinical features, 61
 deferoxamine and, 522
 definition of, 58, 59
 drug-induced, 351
 evaluation, 64–5
 extrahepatic complications, 61–2
 bone disease, 64
 cardiovascular, 62
 hematologic, 62, 66–7
 immunologic, 63
 malnutrition, 64, 71–2
 metabolic, 62
 neurologic, 62–3, 70–1
 pulmonary, 62
 renal, 63, 69–70
 GALD-NH, 526
 glycogen storage diseases type IV, 474–5
 hepatocellular carcinoma risk, 61
 HH treatment and, 521
 in IAH, 323, 324, 325–7
 liver function assessment and prognosis, 65
 dynamic tests, 65–6
 serum liver proteins, 65
 management, 66
 ascites, 67–8
 coagulopathy, 66–7
 HE, 70–1
 HRS, 69–70
 nutritional therapy, 71–2
 spontaneous bacterial peritonitis, 68–9
 varices, 68
 in NAFLD/NASH, 655
 pathophysiology, 59–61
 pre-transplant mortality assessment, 66
 spontaneous bacterial peritonitis in, 63, 68–9
 Wilson disease, 492, 497–8, 500
- cisplatin
 drug-induced liver disease, 358–9
- for hepatic tumors, 795
- citrin deficiency
 laboratory diagnosis, 414
 urea cycle disorders, 702
- citrullinemia type 1, 701
- citrullinemia type 2, 702
- clarithromycin, 361–2
- clavulanic acid. *See* amoxicillin-clavulanic acid
- clofazimine, 388
- Clonorchis sinensis*, 722–4
- clopidogrel, post-transplant, 817
- clotting factors, cirrhosis, 65
- cloxacillin, 367
- CMV. *See* cytomegalovirus
- CNI, CNII. *See* Crigler-Najjar syndrome
- CNIs. *See* calcineurin inhibitors
- CNS. *See* central nervous system
- coagulation disorders, 735
 ALF complications and management, 51
 cirrhosis, 62, 66–7
 LFTs for, 98–9
 vitamin K deficiency, 62, 84–5, 98–9, 109–10, 139–40, 163–4, 204–6, 209, 223, 689
- cocaine, 361
- coccidioidomycosis, 725–6
- codeine, 349
- coenzyme Q10, for
 mitochondrial
 hepatopathies, 646, 647
- coffee consumption, protection against PSC, 334
- cognitive impairment
 in Alagille syndrome, 231–2
 cholestasis, 142–3
 nitisinone treatment, 563
 post-transplant, 828–30
 in transferase-deficiency galactosemia, 459, 461
- colesevelam hydrochloride
 for hyperlipidemia and xanthomas in cholestasis, 128
 for pruritus of cholestasis, 125
- colestipol
 for cholestasis, 119
 for hyperlipidemia and xanthomas in cholestasis, 128
 for pruritus of cholestasis, 125
- collagen vascular disease, 739
 Behçet disease, 740
 dermatomyositis, 740
 JIA, 739–40
 Kawasaki disease, 256–7, 741
 mixed connective tissue disease, 740
 Sjögren syndrome, 257, 740
 SLE, 740
 systemic sclerosis, 740
- comfrey, 363
- COMMD1* gene, 486–7
- common bile duct, spontaneous perforation, 179
- common variable immunodeficiency, 324–5, 388
- compensated cirrhosis, 59
- complementary and alternative medicines, 363–4, 742–3
- Complex. *See* NADH-CoQ reductase
- Complex II. *See* succinate-CoQ reductase
- Complex III. *See* reduced CoQ-cytochrome c reductase
- Complex IV. *See* cytochrome c oxidase
- computed tomography (CT)
 acalculous cholecystitis, 259
 CF-associated liver disease, 448
 gallstones, 268, 269
 hepatic tumors in, 774, 775, 776
 tyrosinemia, 558
 Wilson disease, 499
- congenital absence, gallbladder, 255
- congenital alloimmune hepatitis. *See* gestational alloimmune liver disease
- congenital disorders of glycosylation (CDG), 455, 475–7
 ATP6VAP1-CDG, 478
 ATP6VAP2-CDG, 478
 biochemical characteristics, 476, 477
 CCDG115-CDG, 478
 copper metabolism in, 511
 phosphoglucomutase deficiency, 477
 phosphomannomutase deficiency, 477
 phosphomannose isomerase deficiency, 477
 Tmem199-CDG, 478
- congenital erythropoietic porphyria (CEP), 530
- clinical features, 542
 description, 542
 diagnosis, 542
 treatment, 542
- congenital heart disease
 in Alagille syndrome, 225–6
 in biliary atresia, 163
 liver disease associated with, 732–3
- congenital hepatic fibrosis (CHF), 750, 751.
See also autosomal recessive polycystic kidney disease
 clinical manifestations, 752–4
 diagnosis, 754
 differential diagnosis, 754
 genetic counseling, 755
 imaging, 754

Shneider

Index

[More In](#)

Index

- CHF (cont.)
laboratory findings, 754
pathology, 750–2
physical examination, 754
surveillance, 755
therapy, 755
- congenital hypothyroidism, 192
- congenital infections, neonatal hepatitis, 147
bacterial, 147–9
histopathology, 147, 148
parasitic, 150
routes of, 147
viral, 150–6
- congenital lactic acidemias, 407–11
- congenital rubella, 151–2
- congenital syphilis, 149
- congenital varicella syndrome, 156
- congenital Zika syndrome (CZS), 156
- congestive hepatopathy, in CF, 443–4
- conjugated bilirubin
excretion of, 27
measurement, 187
- conjugated cholic acid, 593–6
- conjugated hyperbilirubinemia
bilirubin metabolism disorders, 197
neonatal cholestasis, 107–8, 109–10, 157
- conjugation
of bile acids, 26–7
bilirubin metabolism, 185, 186, 350–1
- constitutive androstane receptor (CAR), 17
agonists, 122
in cholestasis pathogenesis, 28–9
- contiguous ABCD1 DXS1357E deletion syndrome (CADD5), 671
- contingent hepatotoxin, 353–4
- conventional interferon- α , for HBV infection, 295–6
- Coombs-positive giant cell hepatitis, 157
- copper
absorption and metabolism, 484–7
in bile, 486–7
for cholestasis, 141–2
hepatotoxicity, 484, 487
histochemical stains, 498
in IFALD pathogenesis, 249
organ distribution, 487
serum, 494
urine, 494–6
- copper chelation therapy
for ICC, 509–10
for ICT, 511
before surgery, 507
for Wilson disease, 488
mechanism of, 491
in pregnancy, 506–7
treatment use, 501–5, 506–7
- copper metabolism disorders. *See also* Wilson disease
in cholestasis, 512
- congenital disorders of glycosylation, 511
- Huppke-Brendel syndrome, 511–12
- ICT, 484, 507, 510
clinical features, 510
diagnostic testing, 510
etiopathogenesis, 510–11
histopathology, 510
treatment, 511
- Indian Childhood Cirrhosis, 484, 507
clinical features, 507–8
diagnosis, 509–10
epidemiology, 507
genetics, 507
histopathology, 508
pathogenesis, 508–9
treatment, 509–10
- manganese retention disorder, 511
- MEDNIK syndrome, 511
- copper uptake protein 1 (CTR1), 484, 485
- COPRO-oxidase, 540–1, 542
- core gene mutations, HBV, 294
- core promoter mutations, HBV, 293
- corneal crystals, tyrosinemia, 563
- cornstarch, glycogen storage disease, 471–2
- corticosteroid therapy
for AIH, 327–8, 329
for cholestasis, 121–2
for drug-induced liver disease, 372
for HLH, 392–3
for post-liver transplant AIH, 330
post-transplant, 817–18
- COX-2. *See* cyclooxygenase-2
- COX17, in copper metabolism, 486
- Coxiella burnetti*, 718–19
- CPEO. *See* chronic progressive external ophthalmoplegia
- CPS deficiency. *See* carbamyl-phosphate synthetase deficiency
- CRAT, 673–6
- Crigler-Najjar syndrome (CNI, CNII)
clinical presentation, 198
diagnosis and treatment, 199–200
drug hepatotoxicity in, 357
pathophysiology, 198–9
- critical illness
hepatic dysfunction
with, 730
secondary sclerosing cholangitis in, 732
- Crohn disease (CD)
cholesterol gallstones in, 266
gallbladder inflammation in, 260
PSC with, 333, 334, 336, 339–40
- CROT, 673–6
- cryptococcosis, 726
- cryptogenic cirrhosis, IAH as cause of, 323
- cryptosporidiosis
in HIV cholangiopathy, 389–90
in sclerosing cholangitis, 384–8
- CT. *See* computed tomography
- CTNNT1 mutations, 784, 788–90
- CTP scoring system. *See* Child-Turcotte-Pugh scoring system
- CTR1. *See* copper uptake protein 1
- CTX. *See* cerebrotendinous xanthomatosis
- cutaneous porphyrias, 534
- cutaneous vascular patterns, portal hypertension, 79
- cyclobilirubin, 193, 194
- cyclooxygenase-2 (COX-2), in hepatic tumors, 796
- cyclophosphamide, 358–9
- cyclosporine
for AIH, 328–9
hepatic metabolism, 349
hepatotoxicity, 361
for HLH, 392–3
- CYP7A1, 676–7
- CYP7A1 deficiency. *See* cholesterol 7 α -hydroxylase deficiency
- CYP7B1 deficiency. *See* oxysterol 7 α -hydroxylase deficiency
- CYP8B1 deficiency. *See* 12 α -hydroxylase deficiency
- CYP27A1. *See* sterol 27-hydroxylase deficiency
- cysteamine, for NAFLD/NASH, 667
- cysteine metabolism, 15
- cystic ducts
double, 256
obstruction of, 268
- cystic fibrosis (CF), 437, 452
CFTR in, 439–40
alternative cholangiocyte channels, 439, 451
channel actions of, 437, 438
innate immunity regulation by, 439
liver function role of, 438–9
modulators of, 451
mutations, 440
regulator actions of, 437–8
cholesterol gallstones in, 266–7
clinical manifestations of liver disease in, 443, 446
biliary tract disease in, 445
- congestive hepatopathy, 443–4
focal biliary and multilobular cirrhosis, 444–5
neonatal cholestasis, 444
steatosis, 444, 445
- definitions of liver disease in, 445
- diagnosis and screening, 445
biochemical evaluation, 446, 447
biomarkers, 449
CT and MRI, 448
elastography, 448, 449
liver biopsy, 448–9
physical examination, 445–6
ultrasonography, 447–8
- gallbladder hypoplasia in, 255
- pathogenesis of liver injury in, 440–1, 442
altered intestinal microbiome, 441
cytokines, 442
mucins, 441
steatosis, 442
stellate cells, 442
toxic bile acids, 442
- potential genetic modifiers, 442
 α_1 -AT deficiency, 443
immune system and antioxidant status, 442–3
meconium ileus, 442
other ion channels, 443
SERPINA1 alleles, 443
- prevalence of liver disease in, 443
- treatment, 449
alternative channels, 451
antifibrotic agents, 452
choleretic agents, 451–2
focal biliary and multilobular cirrhosis, 449–50
gene therapy, 451
for hepatic steatosis, 449
intestinal microbiome alteration, 451
liver transplantation, 450–1, 805
modulators of CFTR function, 451
nutritional management, 450
for portal hypertension, 450–1
UDCA therapy, 120
- cystic fibrosis transmembrane conductance regulator (CFTR), 439–40
alternative cholangiocyte channels, 439, 451
channel actions of, 437, 438
innate immunity regulation by, 439

Shneider

Index

[More I](#)

Index

- liver function role
of, 438–9
modulators of, 451
mutations, 440
regulator actions of, 437–8
cysts. *See also* choledochal cysts;
fibrocystic liver disease;
polycystic kidney disease
echinococcal, 720–1
solitary non-parasitic liver,
750, 751
cytochrome *c* oxidase, 628–30
cytochromes P450
developmental changes, 350
in early development, 17–18
families and subfamilies, 349
inducibility, 349
polymorphisms, 349
cytokeratin-18 fragments, 660
cytokines, in CF, 442
cytomegalovirus (CMV)
calculous cholecystitis in, 258
ALF in, 42–3
neonatal hepatitis, 150
post-transplant infection,
816–17, 820–1
in sclerosing cholangitis, 386
cytosine arabinoside, 358–9
CZS. *See* congenital Zika
syndrome
- DAA. *See* direct acting anti-virals
dacarbazine, 358–9
daclizumab, 395
dactinomycin, 358–9
DAO, 677–8
D-bifunctional protein (DBP)
deficiency, 684
DCD. *See* donation after cardiac
death
DCDC2 gene, 29
de novo AIH, 330, 825–6
debranching enzyme deficiency.
See amylo-1,6-glucosi-
dase deficiency
debrisoquine, 349
deceased donor, liver
transplantation, 809–10,
811
decompensated cirrhosis, 59
DEC2R2, 673–6
deferasirox, 522
deferiprone, 522
deferoxamine, 522, 523
definitive endoderm, 1
delta hepatitis virus. *See* hepatitis
D virus
dental hygiene, cholestasis, 143
deoxyguanosine kinase
(DGUOK) deficiency,
634, 638
dermatomyositis, 740
designer drugs, 361
development. *See also* liver
development
cholestasis management for,
142–3
developmental delay
- nitrosone treatment for
tyrosinemia and, 563
post-transplant, 828–30
dexame, for HLH, 392–3
dexamethasone, for HLH, 392–3
dextromethorphan, hepatic
metabolism, 349
DGUOK deficiency. *See*
deoxyguanosine kinase
deficiency
DGUOK mutations, 634, 638, 804
DHA. *See* docosohexanoic acid
diabetes mellitus
gallbladder motility in, 260
hepatic involvement in, 741–2
NAFLD/NASH association
with, 655, 656
neonatal jaundice, 192
post-transplant, 828
Wilson disease, 494
diclofenac, hepatotoxicity, 367
diet
for ascites, 67
copper in, 484, 485
fat restriction in, 623
for fructose metabolism
disorders, 466
for galactosemia, 460–1
glycogen storage disease,
471–2
for hyperlipidemia and
xanthomas in cholestasis,
129
metabolic stresses and, 561–2
for mitochondrial
hepatopathies, 646–7
for NAFLD/NASH, 666–8
peroxisomal disorders, 689
in PSC development, 334
for tyrosinemia, 560–2
dietary supplements, 363–4,
742–3
differentiation, hepatoblast
hepatoblast potential, 5
transcriptomic signatures at
single-cell resolution, 5–7
1,25-dihydroxyvitamin D. *See*
vitamin D
DILI. *See* drug-induced liver
disease
diltiazem, 349
2,3-dimercaptopropanol, 488
dinitrophenylhydrazine (DNPH)
test, 402–3
dip strip, 402–3
diphenhydramine, for Alagille
syndrome, 236
diphenylhydantoin
hepatotoxicity, 368
for neonatal jaundice, 195
direct acting anti-virals (DAA),
for HCV infection, 153,
309–10, 311, 312
direct bilirubin. *See* conjugated
bilirubin
diuretics, for ascites, 68
diverticuli, gallbladder, 256
DNA
HBV, 285, 286–7, 288, 289
indication for antiviral
therapy, 294–5
mitochondrial, 628–9, 631–2
deletions in ethanol
hepatotoxicity, 641–2
deletions in primary
mitochondrial
hepatopathies, 634,
635–40
sequencing, 644, 645
DNA ploidy analysis, in HB,
791–2
DNA samples, IEM, 413
DNA sequencing technologies
IEM diagnosis, 403–5
mitochondrial hepatopathies,
644, 645
Wilson disease, 496
DNPH test. *See* dinitrophenyl-
hydrazine test
docosohexanoic acid (DHA),
132–3, 689
Domino transplantation, 811
donation after cardiac death
(DCD), 808
donor organs, liver
transplantation, 807–8,
809
deceased donor assessment,
809–10, 811
graft selection and size, 808–9
living donor evaluation, 810
procurement, 810–11
double gallbladder, 256
Down syndrome. *See* trisomy 21
doxorubicin, 795
D-penicillamine
for ICC, 509–10
in pregnancy, 506–7
before surgery, 507
for Wilson disease, 488, 501–4,
506–7
DPM. *See* ductal plate
malformation
DRESS syndrome, 351
drug hypersensitivity syndrome,
351, 352
drug metabolism. *See* hepatic
drug metabolism
drug-induced liver disease
(DILI), 348
acetaminophen, 38–9, 45,
352–4, 355–7, 372
ALF, 38–40, 45, 351, 372
amiodarone, 357–8
anti-neoplastic agents, 358–9,
736, 737
aspirin, 359
atomoxetine, 359–60
azathioprine, 360
biopsy, 40
bosentan, 360
carbamazepine, 360–1
cholestasis pathogenesis, 30,
351, 352
classification of hepatotoxins,
353–4
clinical presentation, 348,
351–5
cocaine, 361
cyclosporine, 361
diagnosis, 372
Ecstasy, 361
erythromycin, 361–2
ethanol, 641–2
felbamate, 362
HAART, 390
haloperidol, 362
halothane, 362–3
hepatic drug metabolism,
348–51
hepatocellular damage
amplification, 352–3
herbal medications, 363–4,
742–3
host idiosyncrasy, 352, 353–4
infliximab, 364
intrinsic hepatotoxicity, 352
isoniazid, 364–5
ketoconazole, 365
lamotrigine, 365
mechanisms of, 352, 353
metabogenetic factors, 353
methotrexate, 365–6
minocycline, 366
mitochondrial dysfunction,
641–2
nevirapine, 366–7
NSAIDs, 367
oral contraceptive
pills, 362
patterns of hepatotoxicity in,
351–5
pemoline, 367
penicillin, 367
phenobarbital, 367–8, 646
phenytoin, 368
propylthiouracil, 368–9
retinoids, 369
reverse transcriptase
inhibitors, 642
risperidone, 369
screening, 372
statins, 369
sulfonamides, 369
terminology, 348
toxic metabolite in, 350,
352–3, 370, 371
treatment of, 372
valproic acid, 39, 370–2, 641,
646
DTaP combination vaccination,
143
dual porphyria, 544
Duarte gene, 460
Dubin–Johnson syndrome
clinical presentation, 200–1
diagnosis and treatment, 201
laboratory diagnosis, 406
pathophysiology, 201
ductal plate, 7, 8
ductal plate malformation
(DPM). *See also* congeni-
tal hepatic fibrosis
in biliary atresia, 162

Shneider

Index

[More In](#) Index

- DPM (cont.)
 developmental underpinnings of, 9
 fibrocystic liver disease, 749, 750
 dynamic function tests, 101
 cirrhosis, 65–6
 dyskinesia, Wilson disease, 492–3
- EBV. *See* Epstein–Barr virus
- ECH1, 673–6
- echinacea, 364
- echinococcal disease, 720–1
- ECM. *See* extracellular matrix
- Ecstasy, 361
- ectopic tissues, gallbladder, 256
- EEG. *See* electroencephalography
- EFAs. *See* essential fatty acids
- EHEs. *See* epithelioid hemangioendotheliomas
- EHHADH, 673–6
- EHPVO. *See* extrahepatic portal vein obstruction
- ehrlichiosis, 717
- elafibranor, 60
- elastography
 CF-associated liver disease, 448, 449
 cirrhosis, 60
 coagulation disorders, 51, 98
 fibrosis, 60, 244, 310–11, 448, 449, 660–1, 733, 754
 IFALD, 244
 methotrexate treatment monitoring, 366
 NAFLD/NASH, 660–1
- electroencephalography (EEG), HE, 48–50
- electron transport proteins. *See* respiratory chain complexes
- embryonal sarcoma
 gallbladder, 260
 hepatic, 780, 790, 791
- emphysema, α_1 -AT deficiency, 417–18, 420–1
- emtricitabine, 642
- encephalopathy. *See* hepatic encephalopathy
- endemic Tyrolean infantile cirrhosis, 507, 510–11
- endocrine disorders. *See also* diabetes mellitus
 adrenal, 741
 hypopituitarism, 192, 741
 thyroid, 741
- endoplasmic reticulum (ER)
 damage in NAFLD/NASH, 656–7
 mutant α_1 -antitrypsin Z in, 425–8
- endoscopic retrograde cholangio pancreatography (ERCP)
 liver complications in
 immunodeficiency, 384, 386
 PSC, 336–8
- endoscopy, for portal hypertension, 83, 84–5
 band ligation, 84, 86, 87–8
 glue injection, 88–9
 primary prophylaxis, 84
 sclerotherapy, 84, 87–8
 secondary prophylaxis, 87–8
- endothelial cells, in hepatic specification, 4–5
- endothelin receptor antagonists, hepatotoxicity, 360
- endotoxins, bacterial, 29–30, 147–8
- end-stage liver disease. *See specific topics*
- energy metabolism, in early development, 12
- energy requirements
 cholestasis, 132
 PN in excess of, 247
- enflurane, 363
- 2-enoyl-CoA hydratases, 615
- Entamoeba histolytica*, 719–20
- entecavir, 296–7
- enterically transmitted non-A, non-B hepatitis, 154
- enterohepatic circulation
 bile formation and, 26–7
 bilirubin metabolism, 184, 186, 187, 188
 disruption of
 for Alagille syndrome, 237
 for pruritus of cholestasis, 127
 in early development, 19
 increased, 191
 pharmacologic management of, 195
- enteropathy, HIV, 389
- enteroviral hepatitis, neonatal hepatitis, 154–5
- environmental toxins, in biliary atresia, 167–8
- enzymatic activity, in early development, 12
- enzymatic assays, mitochondrial hepatopathies, 645–6
- enzyme therapy
 for Gaucher disease, 575–6
 mucopolysaccharidoses, 589
- ephedra, 364
- epimerase-deficiency
 galactosemia, 455, 461–2, 468
- epithelioid
 hemangioendotheliomas (EHEs), 780, 789, 790
- epoxide hydrolase, 349–50
- epoxide hydroxylase, 18–19
- EPP. *See* erythropoietic protoporphyria
- Epstein–Barr virus (EBV)
 ALF in, 42–3
 post-transplant, 816–17, 820–1
 XLP disease triggered by, 393–4
- ER. *See* endoplasmic reticulum
- ERCP. *See* endoscopic retrograde cholangio pancreatography
- ergocalciferol, for cholestasis, 136–7
- erythrocyte zinc protoporphyria, 540
- erythromycin
 hepatic metabolism, 349
 hepatotoxicity, 361–2
 for IFALD, 252
- erythropoietic protoporphyria (EPP)
 clinical features, 542–3
 diagnosis, 543
 genetics, 542
 treatment, 543–4
- Escherichia coli*
 acalculous cholecystitis in, 258
 hyperbilirubinemia associated with, 710
 neonatal hepatitis, 149
 in transferase-deficiency galactosemia, 457
- esophageal varices, 74–5, 79, 83–4. *See also* endoscopy
- emergency therapy, 84–5
 endoscopic, 86
 mechanical, 86
 pharmacologic, 85
 surgical and interventional radiologic, 86–7
 endoscopy, 83, 84–5, 86
 pre-primary prophylaxis, 84
 primary prophylaxis, 84
 screening, 89–90
 secondary prophylaxis, 87–9
- essential fatty acids (EFAs)
 for Alagille syndrome, 237
 for cholestasis, 132–3
 in IFALD, 247–9, 250–1
 replacement of, 623
- essential fructosuria, 462, 466
- estrogens
 gallstones associated with, 265
 hepatotoxicity, 362
- etanercept, hepatotoxicity, 364
- ethanol hepatotoxicity, 641–2
- ether lipid biosynthesis, 674, 677
- ethical issues, liver transplantation, 811
- ethylmalonic acidemia, 412
- etoposide
 for hepatic tumors, 795
 for HLH, 392–3
- European Society for Blood and Marrow Transplantation, diagnostic criteria for hepatic VOD/SOS, 737
- European Society of Pediatric Gastroenterology, Hepatology and Nutrition, HCV treatment recommendations, 310, 312
- exchange transfusion
 for GALD, 527
- for neonatal jaundice, 194–5
- exome sequencing, IEM diagnosis, 403–5
- extracellular matrix (ECM), cirrhosis
 pathophysiology, 59–61
- extrahepatic bile duct disorders, 162. *See also* biliary atresia; choledochal cysts
- extrahepatic cholestasis, neonatal, 107, 157–8
- extrahepatic portal vein obstruction (EHPVO), 81, 89
- extravascular blood, neonatal jaundice, 191
- eye
 Alagille syndrome
 abnormalities, 229–31
 lenticular changes in
 galactosemia, 458–9, 461
 vitamin A deficiency, 133–6
 Wilson disease presentations
 Kayser–Fleischer ring, 490, 491, 499, 500
 sunflower cataract, 490–1
- facial features, Alagille syndrome, 229, 230
- FAH. *See* fumarylacetoacetate hydrolase
- FALD. *See* Fontan-associated liver disease
- false neurotransmitter hypothesis, 70–1
- familial adenomatous polyposis (FAP), 770, 771
- familial hepatocellular cholestasis, 204, 218. *See also* progressive familial intrahepatic cholestasis
- Aagenaes syndrome, 216
 ARC syndrome, 216–17
 familial hypercholanemia, 217–18
 FXR deficiency, 218
 MYO5B mutations, 217
 NAIC, 218
 neonatal hepatitis, 157
 osteo-oto-hepato-enteric syndrome, 217
 TJP2 deficiency, 217
- familial HLH, 392–3
- familial hypercholanemia, 217–18
- familial hypobetalipoproteinemia, 267
- family support, for cholestasis, 143
- Fanconi anemia, 771–4
- FAO. *See* fatty acid oxidation
- FAP. *See* familial adenomatous polyposis
- FAR1, 677
- FAR2, 677
- Farber disease, 578
- farnesoid X receptor (FXR)
 agonists, 28–9, 122, 123

Shneider

Index

[More I](#)

Index

- in bile acid synthesis, 676–7
in cholestasis pathogenesis, 28–9
in early development, 22–3
in hepatic adaptation to bile acid retention, 30–1
phytosterol effects on, 247–9
FARS2 deletions, 639–40
FAS pathway, in HB, 787
Fasciola hepatica, 724
fasting, 611, 621–2
fat, intake of
for Alagille syndrome, 237
cholestasis, 132
fat metabolism, in early development, 15–16
fatigue, cholestasis, 127–8
fat-soluble vitamins
for Alagille syndrome, 237
bile acid synthesis defects and, 598, 599
for cholestasis, 133–40
fatty acid oxidation (FAO)
acyl-CoA dehydrogenases, 613–15
in early development, 15–16
energy production with, 611
2-enoyl-CoA hydratases, 615
final products of, 617
3-hydroxyacyl-CoA dehydrogenases, 616
3-ketoacyl-CoA thiolases, 616–17
mechanism of, 613, 614
mitochondrial functions and, 631
of odd-chains, 616, 617
regulation of, 611–13
short-chain enoyl-CoA hydratase, 616
trifunctional protein, 615, 616
unsaturated, 617
fatty acid oxidation (FAO) disorders
ACAD9 deficiency, 618
acute management of, 622
in ALF, 41–2
B vitamin supplementation for, 624
bezafibrate for, 624
carnitine
palmitoyltransferase-IA deficiency, 617
carnitine
palmitoyltransferase-II deficiency, 617–18
carnitine shuttle defects, 617
carnitine transport defects, 617
diagnosis of, 620, 621
dietary fat restriction for, 623
essential fatty acid replacement for, 623
fasting avoidance with, 621–2
genetics of, 611, 612
glutaric acidemia type II, 619–20
HAD deficiency, 619
incidence of, 611
laboratory diagnosis, 411–13, 414
L-carnitine supplementation, 622–3
LCHAD deficiency, 618
MCAD deficiency, 618–19
medium-chain 3-ketoacyl-CoA thiolase, 619
newborn screening, 415
night-time hypoglycemia prevention, 622
pregnancy and, 624
SCAD deficiency, 619
sudden infant death, 620
treatment of, 621
triheptanoate for, 623–4
VLCAD deficiency, 618
fatty acids
for Alagille syndrome, 237
for cholestasis, 132–3
in early development, 15–16
in IFALD, 247–9, 250–1
unsaturated, 617
fatty liver, 351. *See also* non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
FDPase deficiency. *See* fructose-1,6-diphosphatase deficiency
felbamate, 362
ferritin, iron overload and, 522
ferroportin, 515, 517, 524
fetus
amino acid metabolism in, 14–15
bile formation in, 21–3
biotransformation in, 16–19
carbohydrate metabolism in, 12–14
enzymatic activity in, 12
hepatic energy metabolism in, 12
hepatobiliary function in, 19–21
lipid metabolism in, 15–16
fever, in liver transplant recipient, 821
FGF. *See* fibroblast growth factor
FGF19, 676–7
FGF19 analogues, for cholestasis, 122–3
FGF induction, in hepatic specification, 3
FHL mutations, 392, 393
fialuridine, 642
FIB-4 score. *See* fibrosis-4 score
fibroblast growth factor (FGF), in hepatic specification, 3
induction signaling, 3
fibrocystic liver disease, 749, 750. *See also* congenital hepatic fibrosis
ADPKD, 759–60
ARPKD, 750, 751, 755–6, 757
Caroli disease, 756–9
Caroli syndrome, 756–9
classifications of, 750
ductal plate malformation in, 9
pathogenesis and animal models, 762–5
genetics, 763
PKD, 762–5
PLD, 761–2
solitary non-parasitic cysts, 750, 751
von Meyenburg complexes, 760–1
fibrosis, 58
bile acids retention in cholestasis, 123
cirrhosis pathophysiology, 59–61
classifications, 58–9
elastography, 60, 244, 310–11, 448, 449, 660–1, 733, 754
IFALD, 243–4
NAFLD/NASH, 655
portal hypertension, 82–3
fibrosis-4 (FIB-4) score, 449
FIC1 mutations. *See* progressive familial intrahepatic cholestasis type 1 (ATP8B1)
Final Rule, liver transplantation, 806
fish oil lipid emulsions, in IFALD, 247–9, 250–1
flavin-containing monooxygenases (FMOs), in early development, 18
floating gallbladder, 256
flucloxacillin, 367
fluconazole, 365
flukes
Clonorchis sinensis, 722–4
Fasciola hepatica, 724
5-fluorouracil, 795
FMOs. *See* flavin-containing monooxygenases
FNH. *See* focal nodular hyperplasia
focal biliary cirrhosis, in CF, 444–5, 449–50
focal nodular hyperplasia (FNH), 779, 782, 787
Fontan-associated liver disease (FALD), 732–3
Forbes disease. *See* glycogen storage disease, type III
foscarnet, 150
fractures, in Alagille syndrome, 228
Francisella tularensis, 715
fructokinase deficiency, 462, 463, 466
fructose
malabsorption, 466
in NAFLD/NASH pathogenesis, 657
fructose-1,6-diphosphatase (FDPase) deficiency, 462, 463, 466–7
fructose-1-phosphate aldolase, 462, 463. *See also* hereditary fructose intolerance
fructose metabolism disorders, 455, 462
biochemistry of fructose metabolism, 462, 463
essential fructosuria, 462, 466
FDPase deficiency, 462, 463, 466–7
HFI, 455, 462, 463
in ALF, 41–2
biochemical features and pathogenesis of toxicity, 464–5
clinical presentation, 463–4
diagnosis, 466
laboratory diagnosis, 405
laboratory findings, 465–6
molecular basis, 463
prognosis, 466
treatment, 466
fucosidosis, 581–2
fulminant HBV infection, 290, 299
fulminant liver failure. *See also* acute liver failure
in HBV infection, 290, 299
in IAH, 323, 324
IEMs, 405–6
tyrosinemia, 555, 558–9
fulminant Wilson disease, 42, 491, 497, 500
fumarase deficiency, 409–11
fumarylacetoacetate, 548–9
fumarylacetoacetate hydrolase (FAH)
assay for, 551
hypersuccinylacetone, 552
tyrosinemia and, 548–9, 550
fumaryl-acetoacetate hydrolase deficiency. *See* hereditary tyrosinemia type 1
functional liver development
amino acid metabolism, 14–15
bile formation during, 21–3
biotransformation, 16–19
carbohydrate metabolism, 12–14
enzymatic activity in, 12
hepatic energy metabolism, 12
hepatobiliary function during, 19–21
lipid metabolism, 15–16
fungal infections, 727
acalculous cholecystitis in, 258
aspergillosis, 727
candidiasis, 725
coccidioidomycosis, 725–6
cryptococcosis, 726
histoplasmosis, 726–7
Penicillium marneffeii, 725
post-transplant, 820–1
Trichosporon cutaneum, 725
furosemide, for ascites, 68
FUT2 mutations, 335
FXR. *See* farnesoid X receptor

Shneider

Index

[More In](#) Index

- FXR deficiency, 218. *See also* familial hepatocellular cholestasis
- G6Pase. *See* glucose-6-phosphatase
- G6PC mutations, 469
- G274D mutations, 235
- galactokinase, 455–7
- galactokinase-deficiency galactosemia, 455, 461, 468
- galactose-1-phosphate uridylyltransferase, 455–7. *See also* transferase-deficiency galactosemia
- galactose mutarotase, 455–7
- galactose mutarotase deficiency galactosemia, 455, 462, 468
- galactosemia, 455
- in ALF, 41–2
- biochemistry of galactose metabolism, 455–7
- laboratory diagnosis, 405
- type I, 455, 457, 468
- biochemical features and pathogenesis of toxicity, 458–9
- clinical presentation, 457–8
- diagnosis, 459
- genetics, 460
- laboratory findings, 458
- molecular basis of, 457
- pathology, 459
- prognosis, 461
- screening, 457, 460
- treatment, 460–1
- type II, 455, 461, 468
- type III, 455, 461–2, 468
- type IV, 455, 462, 468
- galactosialidosis, 583
- GALD. *See* gestational alloimmune liver disease; neonatal hemochromatosis
- GALK1 mutations, 461
- gallbladder
- congenital anomalies of, 255–6
- embryologic development of, 255
- gallbladder disease. *See also* gallstones
- acalculous, 256
- cholecystitis, 258–9
- cholesterolosis, 260–1
- gallbladder dyskinesia, 260
- hydrops, 256–8
- milk of calcium bile, 260–1
- porcelain gallbladder, 260–1
- calculous, 261
- chronic, 268–9
- treatment, 269–70
- in systemic inflammatory disorders, 260
- tumors, 260
- gallbladder distension, transient, 257–8
- gallbladder dyskinesia, 260
- gallbladder finding in biliary atresia, 169, 170, 171
- gallbladder hydrops, 256–8
- gallbladder sludge, 23, 263–4
- gallbladder stasis, 265
- gallstones
- black pigment, 261–3
- chronic hemolytic disease with, 263, 270
- cirrhosis and chronic cholestasis with, 264
- miscellaneous conditions associated with, 264
- TPN-related, 263–4
- brown pigment, 261–3
- conditions predisposing to, 264
- causes, 262, 263
- cholesterol, 261–2, 264–6
- conditions predisposing to, 266–7
- genetic predisposition to, 267
- treatment, 269–70
- classification, 261–2
- clinical features, 267–8, 269
- incidence and prevalence, 261
- neonatal, 23
- in Pima Indians, 265–6
- silent, 263–4, 267–8, 270
- treatment, 269–70
- Wilson disease, 492
- GALT mutations, 457, 460
- gamma-glutamyltransferase (GGT)
- NAFLD/NASH, 660
- neonatal cholestasis, 113–14
- in PSC, 336
- test description, 97
- gamma-immunoglobulins, 394–5
- gamma-tocopherol, for cholestasis, 137–9
- ganciclovir, 150
- gastrointestinal motility, in IFALD pathogenesis, 246
- gastrointestinal system
- ALF complications and management
- ascites, 51
- bleeding, 51
- pancreatitis, 51
- HIV enteropathy, 389
- gastroschisis, in IFALD pathogenesis, 246–7
- Gaucher disease
- bone marrow and liver findings in, 574, 575
- clinical subtypes of, 573–4
- diagnosis of, 575
- genetic mutation in, 570–3, 575
- hepatomegaly in, 574–5
- liver biopsies with, 575
- pathology of, 575
- treatment of, 575–6
- GB virus C, 154
- GBE1 mutations, 474
- GDF15. *See* growth differentiation factor 15
- gemcitabine, 795
- gene therapy
- for α_1 -AT deficiency, 432
- for CF, 451
- mitochondrial hepatopathies, 648
- for tyrosinemia, 566
- Wilson disease, 506
- general pediatric care, for cholestasis, 142
- genetics and genetic testing. *See also* prenatal genetic testing; *specific genes*
- Alagille syndrome, 234–6
- autoimmune hepatitis, 322–3
- benign recurrent intrahepatic cholestasis, 207
- bile acid synthesis defects, 593, 594
- biliary atresia, 166
- CHF, 754
- cholangiocarcinoma, 770–4
- cholestasis, 29, 108, 109, 113
- cholesterol gallstones, 267
- congenital hepatic fibrosis, 754, 755
- cystic fibrosis, 442–3
- drug-induced liver disease, 353
- Dubin–Johnson syndrome, 201
- erythropoietic protoporphyria, 542
- fatty acid oxidation disorders, 611, 612
- fibrocystic liver disease, 763
- galactosemia type I, 460
- Gaucher disease, 570–3, 575
- Gilbert syndrome, 198
- HCC, 770–4, 787–8
- hemangiomas, 790
- hepatoblastoma, 782–7, 793
- hepatoblastoma (HB), 770–4
- hepatocellular adenoma, 788–90
- hereditary hemochromatosis, 516–18, 519, 522
- Indian Childhood Cirrhosis, 507
- juvenile hereditary hemochromatosis, 521–2
- mesenchymal hamartoma, 790
- mitochondrial hepatopathies, 631–2, 634, 643, 644, 645, 648
- mucopolidosis types II and III, 590
- mucopolysaccharidoses, 587
- NAFLD/NASH, 657–9
- neonatal cholestasis, 113
- Niemann–Pick disease type C, 579, 580–1
- peroxisomal disorders, 678–9
- PFIC, 109
- PFIC1, 207
- PFIC2, 210
- PFIC3, 214–15
- primary sclerosing cholangitis, 333–4
- Rotor syndrome, 200
- transferase-deficiency galactosemia, 460
- tumors of liver, 770–4, 782–90, 791, 793
- tyrosinemia, 549–50, 551, 552
- before valproic acid therapy, 371–2
- vascular tumors, 790
- Wilson disease, 484, 485–6, 488, 489, 496, 641
- genome-wide association studies (GWAS), 102
- genomic editing, for α_1 -AT deficiency, 432, 433
- genomic sequencing, IEM diagnosis, 403–5
- genotype–phenotype correlations, in Alagille syndrome, 235
- germader, 364
- gestational alloimmune liver disease (GALD), 394
- in ALF etiology, 40–1
- classification of, 523
- diagnosis of, 525–6
- etiology and pathogenesis of, 523–4
- laboratory diagnosis, 406
- liver transplantation, 527, 803
- medical therapy for, 527
- pathology of, 524–5
- preventive therapy for, 527
- GFM1 deletions, 634, 639
- GGT. *See* gamma-glutamyltransferase
- giant cell hepatitis
- Alagille syndrome, 224–5
- Coombs-positive, 157
- paramyxovirus infection, 155
- giant cell transformation neonatal cholestasis, 107–9
- neonatal hepatitis, 150, 158
- Gilbert syndrome
- clinical presentation, 195
- diagnosis and treatment, 196–8
- drug hepatotoxicity in, 349–50, 357
- pathophysiology, 195–6, 197
- glecaprevir/pibrentasvir (Mavyret), 153
- globulins, serum, 101–2
- α -1,4 glucan-6-glycosyl transferase deficiency, 467, 474
- biochemical and pathologic features, 474–5
- biochemistry of glycogen metabolism, 467–8

Shneider

Index

[More I](#)

Index

- clinical presentation, 474
laboratory findings, 474
molecular basis, 474
treatment, 475
- glucocorticoid therapy
for AIH, 328
for cholestasis, 121–2
for PSC, 341–2
- glucose
in early development, 12–14
for glycogen storage disease
type IA, 471–2
type IB, 472
- glucose-6-phosphatase (G6Pase)
biochemistry of glycogen
metabolism, 467–8
deficiency, 468–72
in fetal hepatic metabolism, 13
- glucose 6-phosphate transporter
biochemistry of glycogen
metabolism, 467–8
deficiency, 472
- glucuronosyltransferases, 349–51
- glutamine metabolism, 15
- glutaric acidemia type II, 619–20
- glutathione peroxidase, 350
- glutathione S-transferases
(GSTs), 18, 349–51
- glycine conjugation, 349–51
- glycogen debranching enzyme
deficiency. *See* amylo-1,6-
glucosidase deficiency
- glycogen metabolism, 12–14
- glycogen storage diseases (GSD),
455
biochemistry of glycogen
metabolism, 467–8
clinical features, 468
enzyme deficiencies in, 467
hepatic tumors in, 471, 771,
773
laboratory diagnosis, 406–7
type IA, 468–9
biochemical characteristics,
469–71
clinical presentation, 469
diagnosis, 471
molecular basis, 469
prognosis, 472
treatment, 471–2
type IB, 472
clinical presentation, 472
molecular basis, 472
treatment, 472
type II, 583–6
type III, 472–3
biochemical and laboratory
findings, 473
clinical presentation, 473
molecular basis, 473
treatment, 473–4
type IV, 474
biochemical and pathologic
features, 474–5
clinical presentation, 474
laboratory findings, 474
molecular basis, 474
treatment, 475
- glycogenesis defects, 467
biochemistry of glycogen
metabolism, 467–8
G6Pase deficiency, 468–72
glucose 6-phosphate
transporter deficiency,
472
- glycolysis, 611
- glycoprotein degradation
disorders, 581
fucosidosis, 581–2
galactosialidosis, 583
sialidosis, 582–3
 α -mannosidosis, 582
- glycosylation defects. *See* conge-
nital disorders of
glycosylation
- G_{M1}-gangliosidosis, 578–9
- GNPAT, 677
- GRACILE syndrome, 634, 639
- graft dysfunction, after liver
transplantation, 821–2
acute rejection, 818
biliary complications, 825
HAT, 812, 822–3
hepatic outflow obstruction,
824–5
hepatitis, 330, 825–6
late onset rejection, 826
PVT, 823–4
screening strategies, 822
- graft selection, liver
transplantation, 807–8,
809
deceased donor assessment,
809–10, 811
graft selection and size, 808–9
living donor evaluation, 810
- graft survival, liver
transplantation, 826–8
- graft-versus-host disease
(GVHD)
stem cell transplantation,
738–9
UDCA therapy, 121
- granulocyte colony-stimulating
factor, for glycogen
storage disease, 472
- green tea extract, 364
- GrisCELLI syndrome, 392
- group A β -hemolytic
streptococci, 715
- growth differentiation factor 15
(GDF15), 644
- growth factors, in hepatic
specification, 3
BMP induction, 3–4
FGF induction, 3
- growth failure
in Alagille syndrome, 231, 237
biliary atresia, 173–4
in cholestasis, 129–30, 142–3
in cirrhosis/end-stage liver
disease, 61, 130–2
post-transplant, 828–30
- GS. *See* Gilbert syndrome
- GSD. *See* glycogen storage
diseases
- GSTs. *See* glutathione S-
transferases
- gut microbiome
in CF, 441, 451
in PSC development, 334
- gut motility, in IFALD
pathogenesis, 246
- GVHD. *See* graft-versus-host
disease
- GWAS. *See* genome-wide
association studies
- gynecomastia, Wilson disease,
494
- H63D *HFE* mutation, 516–18,
519, 520
- HAA anemia. *See* hepatitis-asso-
ciated aplastic anemia
- HAART, hepatotoxicity, 390
- HACL1, 676
- HAD. *See* 3-hydroxyacyl-CoA
dehydrogenase
- haloperidol, 362
- halothane, 362–3
- HAMP* gene, 521–2, 524
- HAO1, 677–8
- Harvoni. *See* ledipasvir-
sofosbuvir
- HAT. *See* hepatic artery
thrombosis
- HAV. *See* hepatitis A virus
- Havrix, 276–7
adverse effects, 277
efficacy, 277
long term immunogenicity,
277
recommendations, 277–8
- Hawkinsinuria, 552
- HB. *See* hepatoblastoma
- HBcAg. *See* hepatitis B core
antigen
- HBsAg. *See* hepatitis B antigen
- HBsAg-negative chronic
hepatitis, 291
- HBIG. *See* hepatitis B
immunoglobulin
- HBsAg. *See* hepatitis B surface
antigen
- HBV. *See* hepatitis B virus
- HCA. *See* hepatocellular
adenoma
- HCC. *See* hepatocellular
carcinoma
- HCCN-NOS. *See* malignant
hepatocellular neoplasm,
not otherwise specified
- HCP. *See* hereditary
coproporphyrria
- HCV. *See* hepatitis C virus
- HDV. *See* hepatitis D virus
- HE. *See* hepatic encephalopathy
- health-related quality of life
(HRQOL)
in Alagille syndrome,
231–2
post-transplant, 829–30
- heart disease
in Alagille syndrome, 225–6
- liver disease associated with,
732–3
- heart transplantation, gallstones
after, 264
- hemangioendotheliomas, 776–7
- hemangiomas
acquired genetic abnormalities
in, 790
AFP levels, 774
clinical presentation, 774, 775
pathology, 776–7, 780, 789
- hematologic disorders
ALF, 51
cirrhosis, 62, 66–7
coagulation disorders, 735
hemoglobinopathies, 734–5
leukemia and lymphoma,
735–6
- hematopoiesis, in early liver, 12
- hematopoietic stem cell
transplantation (HSCT).
See also allogeneic stem
cell transplantation
gallbladder hydrops after, 257
in HBV infection, 391
for HLH, 392–3
for MNGIE, 638
for sclerosing cholangitis in
immunodeficiency, 387,
388
- heme biosynthesis
enzymatic steps in, 530–2
porphyrias and, 530
regulation of, 532–3
- hemin, 565
- hemochromatosis. *See* hereditary
hemochromatosis; juve-
nile hereditary hemo-
chromatosis; neonatal
hemochromatosis
- hemoglobinopathies, 734–5
- hemojuvelin, 521–2
- hemolysis, Wilson disease, 493
- hemolytic disease, black pigment
gallstones in, 263, 270
- hemophagocytic
lymphohistiocytosis
(HLH)
acalculous cholecystitis in, 258
in ALF, 40
GALD-NH, 526
in immunodeficiency, 387,
391–2
diagnostic criteria, 392
familial, 392, 393
treatment, 392–3
liver transplantation, 804
- hemorrhage. *See also* variceal
hemorrhage
Alagille syndrome, 226
ALF, 51
post-transplant, 817
- hemosiderosis, 522
- Henoch-Schönlein purpura, 257
- HEP. *See* hepatoerythropoietic
porphyria
- heparin therapy, post-transplant,
817

Shneider

Index

[More In](#)

Index

- hepatectomy, liver
transplantation, 811, 822–3
- hepatic abscess. *See* liver abscess
- hepatic artery buffer response, 730
- hepatic artery thrombosis (HAT), 812
- hepatic cysts. *See* cysts
- hepatic diverticulum/bud, 1, 2, 255
expansion, 1, 2
liver-specific gene expression in, 1–3
BMP induction, 3–4
endothelial cell signaling, 4–5
FGF induction, 3
- hepatic drug metabolism
balance between phase I and phase II processes, 348–9
cytochromes P450, 17–18, 349, 350
developmental changes, 350–1
in early development, 16–19
mitochondria role in, 350, 371
phase II enzymes, 349–51
toxic metabolism, 350
- hepatic encephalopathy (HE), 36, 53
ALF complications and management, 48–50
cirrhosis, 62–3, 70–1
clinical features, 61
- hepatic hypoperfusion, neonatal jaundice, 192
- hepatic iron index, 519
- hepatic osteodystrophy
cholestasis, 130
cirrhosis, 64
- hepatic outflow obstruction
in ALF, 45–6
after liver transplantation, 824–5
- hepatic regeneration. *See* regeneration
- hepatic sinusoidal obstruction syndrome, 121
- hepatic steatosis. *See* steatosis
- hepatic tumors. *See* tumors of liver
- hepatic vein thrombosis, 362
- hepatic veno-occlusive disease. *See* veno-occlusive disease
- hepatic venous outflow obstruction, 733–4
- hepatic venous pressure gradient (HVPG), 83
- hepatitis. *See also* autoimmune hepatitis; gestational alloimmune liver disease; neonatal hepatitis; non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
activated CD8⁺ T cell, 38, 40
Alagille syndrome, 222–3
 α_1 -AT deficiency, 418
chronic graft, 825–6
drug-induced, 324, 348, 351–2
hypoxic, 731–2
post-liver transplant, 330, 825–6
Trichosporon, 725
typhoid fever, 714
Wilson disease
acute, 491, 497, 499–500
chronic, 491–2, 497, 500
- hepatitis A virus (HAV), 273
active immunization, 276–8
acute illness, 276
ALF in, 42
atypical, 275–6
clinical aspects and pathogenesis, 275
current status, 278
diagnosis, 275
epidemiology, 273–5
neonatal hepatitis, 152
passive immunization, 276
prevention, 276
public health implications, 278
treatment, 276
viral characteristics, 273
- hepatitis A virus (HAV) vaccine, 276–7
adverse effects, 277
efficacy, 277
long term immunogenicity, 277
recommendations, 277–8
- hepatitis B core antigen (HBcAg), 285, 286
- hepatitis B immunoglobulin (HBIG), 152, 298, 395
- hepatitis B surface antigen (HBsAg), 285, 286–7, 288
carrier mothers, 152, 285, 289, 292–3, 298
indication for antiviral therapy, 294–5
neonatal hepatitis, 152
spontaneous clearance, 291
- hepatitis B virus (HBV)
ALF in, 42
factors affecting course of, 292, 293
genotypes and viral titers, 293
host factors, 293
maternal factors, 292–3
mutations, 290, 293–4
viral factors, 293–4
future research directions, 300
genomic structure, 285, 286
global epidemiology, 287–9
HCC association with, 287, 299, 769–70
HDV coinfection, 153–4
hepatocyte entry by, 27
HIV coinfection, 390
in immunodeficiency, 388–9
liver histology, 292
natural history, 289
acute infection, 290
chronic infection, 290–1
fulminant infection, 290, 299
immune tolerance phase, 290
inflammatory phase, 290–1
low replicative phase, 291
occult infection, 291, 300
reactivation phase, 291
spontaneous HBsAg clearance, 291
neonatal hepatitis, 152–3
prevention, 297–8
active and passive immunization, 298
current immunization program problems, 299–300
long-term immunogenicity and need for booster doses, 299
universal vaccination, 298, 299
WHO recommendations, 298
- in primary immunodeficiencies, 390–1
replication, 285, 287
serologic markers, 286–7, 288
terminology, 286
transmission, 285, 287–9
treatment with antivirals, 294, 295
combination therapy, 297
indications, 294–5
interferons, 153, 295–6, 297
nucleoside/nucleotide analogues, 153, 296–7
treatment with new therapeutic strategies, 297
viral characteristics, 285–7, 288
- hepatitis B virus (HBV) vaccine, 152, 285
universal vaccination, 298
current programs for, 298
effectiveness in infection prevention, 299
long-term immunogenicity and need for booster doses, 299
problems with current program, 299–300
reduction of HCC, 299
reduction of mortality in fulminant infection, 299
WHO recommendation for, 298
- WHO recommendation for, 298
- hepatitis Be antigen (HBeAg), 285, 286–7, 288, 290
carrier mothers, 152, 285, 289, 292–3, 298
- hepatitis C virus (HCV), 304
ALF in, 42
clinical features, 308–9
liver histology, 308
natural history, 308–9
non-hepatic consequences, 309
progression potential, 309
diagnosis, 307–8
epidemiology, 305–7
genotypes, 306
HIV coinfection, 153, 307, 313, 390
in immunodeficiency, 388–9
immunopathogenesis of infection, 305
neonatal hepatitis, 153
pathology, 304–5
in primary immunodeficiencies, 391
transmission, 306–7, 313
treatment
DAAs, 153, 309–10, 311, 312
general management, 310–11, 313
liver transplantation, 313
ribavirin and interferon, 153, 310, 312
viral persistence, 305
virology, 304, 305
- hepatitis C virus (HCV) vaccine, 313
- hepatitis D virus (HDV), 153–4
- hepatitis E virus (HEV), 273
ALF in, 42
clinical aspects and pathogenesis, 280
diagnosis, 280
epidemiology, 279–80
in immunodeficiency, 388–9
management and prevention, 280–1
neonatal hepatitis, 154
viral characteristics, 278–9
- hepatitis E virus (HEV) vaccine, 280–1
- hepatitis G virus (HGV), 154
- hepatitis-associated aplastic (HAA) anemia, 51
- hepatobiliary disease, 162
- hepatobiliary function, in early development, 19–21
- hepatobiliary scintigraphy, neonatal cholestasis, 112
- hepatoblastoma (HB), 769
acquired genetic abnormalities in, 782–7, 793
clinical presentation, 774, 775
constitutional genetic and metabolic abnormalities, 770–4
diagnosis, 774, 775, 776

Shneider

Index

[More I](#)

Index

- epidemiology, 769–70
 etiology, 770, 771
 pathology, 776–7, 779, 781, 791
 blastemal, 777, 782
 HCC compared with, 778–9, 786
 immunostaining, 777, 785
 macrotrabecular, 778–9, 786
 mixed, 777, 784
 small cell undifferentiated, 777–8, 782
 teratoid, 777, 784
 prognostic considerations, 791–2, 794
 radiotherapy, 796
 staging, 775–6, 777, 778, 779
 treatment, 793
 chemotherapy, 795
 liver transplantation, 795, 804–5
 multidrug resistance in, 796
 surgery, 793–4
 TACE, 795–6
- hepatoblasts, 2
 differentiation of
 hepatoblast potential, 5
 transcriptomic signatures at single-cell resolution, 5–7
 in ductal plate, 7, 8
 gene expression, 5–7
 hepatocellular jaundice, 351
 glycogen storage diseases, 471
 hepatocellular adenoma (HCA)
 acquired genetic abnormalities in, 788–90
 glycogen storage diseases, 471, 771, 773
 oral contraceptive use associated with, 362
 pathology, 776–7, 781–2
 hepatocellular carcinoma (HCC), 769
 acquired genetic abnormalities in, 787–8
 in AIH, 329–30
 in Alagille syndrome, 224, 771
 α_1 -AT deficiency, 418
 in BSEP deficiency (ABCB11 – PFIC2), 209, 210, 212
 clinical presentation, 774, 775
 constitutional genetic and metabolic abnormalities, 770–4
 diagnosis, 774, 775, 776
 epidemiology, 769–70
 HBV infection association with, 287, 299, 769–70
 HH treatment and, 521
 in NAFLD/NASH, 655
 oral contraceptive use associated with, 362
 pathology, 776–7, 779, 787
 HB compared with, 778–9, 786
 treatment
 chemotherapy, 795
 liver transplantation, 795, 804–5
 surgery, 793–4
 TACE, 795–6
 tyrosinemia, 553–4, 555, 559
 Wilson disease, 492, 771
 hepatocellular necrosis, in ALF, 46–7, 48
 hepatocyte growth factor (HGF)
 in HB, 786
 in hepatic specification, 3
 hepatocyte transplantation, 811
 for ALF, 53
 for α_1 -AT deficiency, 433
 for tyrosinemia, 566
 hepatocytes
 bile retention in
 injury, 118
 response, 27–9, 30–1
 bilirubin uptake by, 183–5
 GALD and, 524, 525
 hepatoblast differentiation into, 5–7
 hepatoerythropoietic porphyria (HEP), 540
 hepatogenesis, 1, 2
 ductal plate malformation, 9
 fibrocystic liver disease and, 749, 750
 hepatoblast differentiation, 5–7
 inductive signaling sources, 1–5
 intrahepatic bile duct development, 7–9
 specification, 1–5
 transcription factors, 5–7
 hepatolenticular degeneration.
See Wilson disease
 hepatomegaly
 acid sphingomyelinase deficiency and, 576
 Alagille syndrome, 222–3
 congenital infection, 147–8, 149
 Farber disease, 578
 Gaucher disease, 574–5
 IEMs, 406–7
 mucopolipidosis II, 590
 neonatal cholestasis, 110
 hepatoportoenterostomy (Kasai procedure)
 in Alagille syndrome, 237
 for biliary atresia, 170, 171, 172, 175
 cholangitis, 170, 171, 173–4, 712–13
 failure, 802
 medical treatment after, 173
 neonatal cholestasis, 110
 reoperation after, 173
 hepatopulmonary syndrome (HPS)
 cirrhosis, 62
 portal hypertension, 79–80
 hepatorenal syndrome (HRS)
 ALF, 51
 cirrhosis, 63, 69–70
 portal hypertension, 80
 hepatotoxicity/hepatotoxins. *See*
also drug-induced liver disease
 in ALF
 etiology, 38–40, 351, 372
 pathogenesis, 45
 copper, 484, 487
 in transferase-deficiency galactosemia, 458
 hepcidin, 515, 517, 521–2, 524
 herbal medications, 363–4, 742–3
 hereditary cholestasis with lymphedema. *See* Aagaens syndrome
 hereditary coproporphyrin (HCP), 533
 clinical features of, 540
 diagnosis of, 540–1
 prevalence of, 540
 treatment of, 541
 hereditary fructose intolerance (HFI), 455, 462, 463
 in ALF, 41–2
 biochemical features and pathogenesis of toxicity, 464–5
 clinical presentation, 463–4
 diagnosis, 466
 laboratory diagnosis, 405
 laboratory findings, 465–6
 molecular basis, 463
 prognosis, 466
 treatment, 466
 hereditary hemochromatosis (HH)
 approach to child with parent with, 520
 children with liver dysfunction and, 520, 521
 classification of, 516
 clinical features of, 518–19
 diagnosis and screening for, 519
 epidemiology of, 518
 genetics of, 516–18, 519, 522
 NH comparison with, 523
 physiology and pathophysiology of, 515–16, 517
 treatment for, 521
 hereditary tyrosinemia type 1, 349–50
 hepatic tumors in, 771
 laboratory diagnosis, 406
 herpes simplex virus
 ALF in, 42–3
 neonatal hepatitis, 151
 heteroplasmy, mtDNA, 629
 heterotopia, in gallbladder, 256
 HEV. *See* hepatitis E virus
 HEX gene, 2
 HFE gene
 mutation analysis of, 520
 mutations of, 516–18, 519, 520
 HFE protein, 515, 517
 HFI. *See* hereditary fructose intolerance
 HGF. *See* hepatocyte growth factor
 HGV. *See* hepatitis G virus
 HH. *See* hereditary hemochromatosis
 HHH. *See* hyperornithinemia-hyperammonemia-homocitrullinuria syndrome
 HHV-6. *See* human herpesvirus 6
 high mobility group box 1 (HMGB1), 38
 HIPPO/YAP, in intrahepatic bile duct development, 9
 histology. *See* biopsy
 histoplasmosis, 726–7
 HIV infection. *See* human immunodeficiency virus infection
 HJV gene, 521–2
 HLA mutations
 in AIH, 322–3
 in PSC, 333–4
 HLH. *See* hemophagocytic lymphohistiocytosis
 HMB-synthase, 531, 535, 544
 HMGB1. *See* high mobility group box 1
 HMG-CoA reductase inhibitors
 hepatotoxicity, 369
 for hyperlipidemia and xanthomas in cholestasis, 129
 HNF1A mutations, 788–90
 HNF1b, in cholangiocyte differentiation, 5
 HNF4a, in hepatocyte differentiation, 5
 HNF6/ONECUT1
 in cholangiocyte differentiation, 5
 in intrahepatic bile duct development, 8–9
 horizontal transmission, HBV, 285, 287–9
 host factors, HBV infection course, 293
 HPS. *See* hepatopulmonary syndrome
 HRQL. *See* health-related quality of life
 HRS. *See* hepatorenal syndrome
 HSCT. *See* hematopoietic stem cell transplantation
 HSD3B7 deficiency. *See* 3 β -hydroxy- Δ^5 C₂₇-steroid oxidoreductase deficiency
 HSD17B4, 673–6
 human herpesvirus 6 (HHV-6)
 ALF in, 42–3
 neonatal hepatitis, 155
 human immunodeficiency virus (HIV) infection
 acalculous cholecystitis in, 258

Shneider

Index

[More In](#)

Index

- (HIV) infection (cont.)
 enteropathy, 389
 HCV coinfection, 153, 307, 313, 390
 liver disease in, 389
 HBV and HCV coinfection, 390
 opportunistic infections in, 389–90
Mycobacterium avium
 complex coinfection, 156
 neonatal hepatitis, 155–6
 sclerosing cholangitis in, 386
 humoral immunity, in AIH, 322
 Huppké-Brendel syndrome, 511–12
 HVPg. *See* hepatic venous pressure gradient
 hydatid cysts, 720–1
 hydrogen peroxide, in mitochondria, 629–30
 hydrophobic bile acids, hepatotoxicity, 642
 hydrops of gallbladder, 256
 clinical features, 257–8
 etiology and pathogenesis, 256–7
 3-hydroxyacyl-CoA dehydrogenase (HAD), 616, 619
 12 α -hydroxylase (CYP8B1) deficiency, 600–1
 25-hydroxylation pathway, side-chain oxidation defect in, 605
 3 β -hydroxysteroid dehydrogenase/isomerase deficiency, 121
 hydroxyzine, for Alagille syndrome, 236
 3 β -hydroxy- Δ^5 C₂₇-steroid oxidoreductase (HSD3B7) deficiency, 601–2
 hyperammonemia. *See* ammonia
 hyperbilirubinemia, 182. *See also* bilirubin metabolism disorders; conjugated hyperbilirubinemia; jaundice; unconjugated hyperbilirubinemia
 American Academy of Pediatrics management guidelines, 189
 bacterial sepsis with, 710
 causes, 189
 cirrhosis, 65
 clinical presentation, 187–9
 management, 193–5
 toxicity of, 193
 hypercholanemia
 familial, 217–18
SLC10A1 mutations in, 27
 hypercholesterolemia, 128
 hyper-IgM syndrome, 384, 385
 AIH association with, 324–5
 sclerosing cholangitis in, 386, 387
 management, 387–8
 opportunistic infection in, 384–8
 hyperimmune immunoglobulins, 395
 hyperlipidemia
 Alagille syndrome, 223
 cholestasis
 pathogenesis, 128
 treatment, 128–9
 glycogen storage diseases, 470
 hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, 702
 hypersuccinylacetone, 552
 hypertyrosinemia, 549, 552
 hyperuricemia, glycogen storage diseases, 470
 hypoglycemia
 in ALF, 51–2
 fructose metabolism disorders, 462, 463–5, 466–7
 galactosemia, 457–8
 glycogen storage diseases
 type IA, 469–70
 type IB, 472
 tyrosinemia, 558
 hypoglycin, 370, 371
 hypogonadism, JHH and, 522
 hypoparathyroidism, 494
 hypophosphatemia, glycogen storage diseases, 470–1
 hypopituitarism
 hepatic involvement in, 741
 neonatal jaundice, 192
 hypoplasia, gallbladder, 255
 hypothyroidism, 192
 hypoxia, hepatic dysfunction with, 730
 hypoxic hepatitis, 731–2
 IAHG. *See* International Autoimmune Hepatitis Group
 IBAT. *See* apical sodium-dependent bile acid transporter; ileal bile acid transporter
 IBD. *See* inflammatory bowel disease
 ibuprofen, 367
 ICC. *See* Indian Childhood Cirrhosis
 ICT. *See* idiopathic copper toxicosis
 ICV. *See* ileocecal valve
 idiopathic copper toxicosis (ICT), 484, 507, 510
 clinical features, 510
 diagnostic testing, 510
 etiopathogenesis, 510–11
 histopathology, 510
 treatment, 511
 idiopathic neonatal hepatitis, 147, 162
 neonatal cholestasis, 107, 108–9
 idiosyncrasy drug hepatotoxicity, 352, 353–4
 IEM. *See* inborn errors of metabolism
 IF. *See* intestinal failure
 IFALD. *See* intestinal failure associated liver disease
 IGF-1. *See* insulin-like growth factor-1
 IGF-2. *See* insulin-like growth factor-2
 ileal bile acid transporter (IBAT) in bile formation and flow, 26–7, 28
 inhibitors for Alagille syndrome, 237
 for pruritus of cholestasis, 127
 ileal exclusion, for pruritus of cholestasis, 127
 ileal resection, cholesterol gallstones in, 266
 ileocecal valve (ICV), 246–7
 ileum, in cholestasis pathogenesis, 31
 imatinib, 796
 immune active phase, HBV infection, 290–1
 immune manipulation, 394–5
 immune response, 383
 CFTR role in, 439
 in drug-induced liver disease, 352–4
 HBV infection course, 293
 liver role in, 45, 383–4
 new pharmacologic developments for manipulating, 394–5
 in PSC, 334–5
 immune system
 cirrhosis effects, 63
 hepatic immunology, 45
 status in CF, 442–3
 immune tolerance phase, HBV infection, 290
 immune-mediated liver injury, 40. *See also* autoimmune hepatitis; autoimmune-like hepatitis
 immunization. *See also specific vaccines*
 cholestasis, 143
 HAV
 active, 276–8
 passive, 276
 HBV, 152, 285
 active, 298
 current program problems, 299–300
 long-term immunogenicity and need for booster doses, 299
 passive, 298
 universal vaccination, 298, 299
 WHO recommendations, 298
 HCV, 313
 HEV, 280–1
 before liver transplantation, 143, 801–2
 immunodeficiency. *See also* hemophagocytic lymphohistiocytosis; human immunodeficiency virus infection
 AIH association with, 324–5
 in ALF, 40
 chronic granulomatous disease, 394
 chronic viral hepatitis in, 388–9
 common primary, 384, 385
 HBV infection in, 390–1
 HCV infection in, 391
 innate and adaptive immune response, 383
 liver complications in, 384, 386
 liver role in immune defenses, 45, 383–4
 metabolic liver-based conditions in, 388, 391
 new pharmacologic developments for, 394–5
 sclerosing cholangitis in, 386, 387
 management, 387–8
 opportunistic infection in, 384–8
 secondary, 384
 XLP disease, 393–4
 immunoglobulin therapy, 394–5
 for GALD, 527
 HAV, 276
 HBV, 152, 298, 395
 immunosuppressive therapy for AIH, 325–7
 budesonide, 328
 calcineurin inhibitors, 328–9
 mycophenolate mofetil, 328
 standard, 327–8, 329
 for ASC, 341–2
 for HLH, 392–3
 for post-liver transplant AIH, 330
 post-transplant, 817–18
 chronic comorbidities, 828
 diagnosis and treatment of rejection, 818
 early postoperative management, 817
 long-term maintenance and tolerance, 818–19
 for PSC, 341–2
 IMTs. *See* inflammatory myofibroblastic tumors
 in utero infection, 147
 inborn errors of metabolism (IEM), 401. *See also specific disorders*

Shneider

Index

[More I](#)

Index

- in ALF, 41–2
 clinical presentations, 401
 laboratory diagnosis, 401–2
 acute or fulminant liver failure, 405–6
 amino acid disorders, 414–15
 cholestasis, 406
 congenital lactic acidemias, 407–11
 DNA sequencing technologies, 403–5
 enzyme defects with acute illness, metabolic decompensation or neurological crisis, 407–15
 FAO disorders, 411–13, 414
 galactosemia, 458
 glycogen storage diseases, 406–7, 473, 474
 hepatocellular dysfunction, 405–6
 hepatomegaly, 406–7
 HFI, 465–6
 mitochondrial hepatopathies, 41–2, 643–4
 organic acidurias, 407
 peroxisomal disorders, 675, 678–9
 routine investigations, 402–3
 specialized investigations, 403
 urea cycle disorders, 413–14
 misdiagnosis, 401–2
 natural history, 401
 newborn screening, 402, 415
 tyrosinemia, 550–1
 signs and symptoms, 402
 indeterminate pediatric ALF, 38
 Indian Childhood Cirrhosis (ICC), 484, 507
 clinical features, 507–8
 diagnosis, 509–10
 epidemiology, 507
 genetics, 507
 histopathology, 508
 pathogenesis, 508–9
 treatment, 509–10
 indocyanine green clearance cirrhosis, 65
 in neonate, 20
 inductive signaling, hepatic specification, 1–3
 BMP induction, 3–4
 endothelial cell signaling, 4–5
 FGF induction, 3
 infant stool color card, 113
 infantile liver failure syndrome type I, 41–2
 infection. *See also* bacterial infections; parasitic infections; viral infections
 in ALF, 42–3, 52
 in cirrhosis, 63, 68–9
 opportunistic
 in HIV cholangiopathy, 389–90
 in sclerosing cholangitis, 384–8
 post-transplant, 819
 early, 820–1
 in long-term follow-up, 821
 patient evaluation, 821
 postoperative management, 816–17
 inflammation
 in ALF, 46
 biliary atresia cause and pathogenesis, 166–7
 in sepsis-associated cholestasis, 29–30, 246, 730–1
 inflammatory bowel disease (IBD)
 cholesterol gallstones in, 266
 PSC with, 333, 334, 336, 339–40
 inflammatory infiltrate, ALF histology, 47–8, 49
 inflammatory myofibroblastic tumors (IMTs), 774, 775
 inflammatory phase, HBV infection, 290–1
 infliximab, 364
 inherited metabolic disease. *See* inborn errors of metabolism
 innate immune response, 383. *See also* immunodeficiency
 CFTR role in, 439
 liver role in, 45
 INR. *See* international normalized ratio
 insulin, in fetal hepatic metabolism, 13
 insulin resistance, NAFLD/ NASH association with, 655, 656, 659
 insulin-like growth factor-1 (IGF-1), in cholestasis, 130
 insulin-like growth factor-2 (IGF-2), in HB, 786
 intellectual impairment. *See* cognitive impairment
 intensive care unit, hepatic dysfunction in, 730
 interferon therapy
 for HBV infection, 153, 295–6, 297
 for HCV infection, 153, 310, 312
 for HEV infection, 281
 International Autoimmune Hepatitis Group (IAIHG), 321
 IAH scoring system, 323
 international normalized ratio (INR)
 test description, 98–9
 vitamin K status, 140
 intestinal bile salt transport inhibitors
 for Alagille syndrome, 237
 for pruritus of cholestasis, 127
 intestinal failure (IF)
 definition, 242
 etiologies, 242
 management, 250
 intestinal failure associated liver disease (IFALD), 242
 clinical presentation and natural history, 242–3
 liver histology, 243–4
 risk factors and pathogenesis, 244–5
 contaminants or toxicities, 249
 patient factors, 245–7
 PN factors, 247–9
 treatment
 IF management, 250
 modification of lipid factors in PN, 250–1
 modification of non-lipid factors in PN, 250
 organ transplantation, 252
 pharmacologic management, 251–2
 intestinal microbiome. *See* gut microbiome
 intestinal stasis, 246
 intestine, reduced bile delivery to
 hepatic osteodystrophy, 130
 nutritional assessment, 130
 nutritional management guidelines, 131
 nutritional therapy, 130–42
 steatorrhea, malnutrition, and growth failure, 129–30
 intra-abdominal pressure, after liver transplantation, 812
 intracranial bleeds, in Alagille syndrome, 226
 intrahepatic bile duct development, 7
 morphogenesis, 7, 8
 Notch signaling, 9, 235
 TGF beta signaling, 8–9
 intrahepatic cholestasis. *See also* familial hepatocellular cholestasis
 bile acid synthesis disorders and, 598, 599
 neonatal, 107, 157–8
 Intralipid, 247–9
 intrauterine transmission, HBV, 289
 intravenous drug abuse (IVDA), 306–7
 intrinsic hepatotoxins, 353–4
 ion channels. *See also* cystic fibrosis transmembrane conductance regulator
 alternative to CFTR, 439, 451
 ion exchange resins
 for hyperlipidemia and xanthomas in cholestasis, 128
 for pruritus of cholestasis, 125, 236
 IPEX syndrome, 324–5
 ipilimumab, 359
 irinotecan, 795
 iron
 for cholestasis, 141
 physiology of, 515–16, 517
 iron overload disorders. *See also specific disorders*
 in children with liver dysfunction, 520, 521
 classification of, 515, 516
 physiology and pathophysiology of, 515–16, 517
 secondary, 522, 523
 ischemia-reperfusion injury, post-transplant, 817
 isoflurane, 363
 isoimmunization, 189–91
 isoniazid, 364–5
 Ivacaftor, 451
 IVDA. *See* intravenous drug abuse
 IVIg, 394–5
 JAGGED1 (JAG1)
 in Alagille syndrome, 222, 226, 233, 234
 bile duct development, 235
 gene identification and mutation analysis, 234
 genetic testing, 235–6
 genotype-phenotype correlations, 235
 Notch signaling pathway effects, 9, 234–5
 in intrahepatic bile duct development, 235
 jaundice. *See also* neonatal jaundice
 Alagille syndrome, 222–3
 ALF, 36
 assessment, 187
 α_1 -AT deficiency, 417–19
 bacterial sepsis with, 710
 biliary atresia, 163–4, 168, 169, 171–3, 175
 drug-induced, 351
 hepatic tumors in, 774
 in IAH, 324
 neonatal cholestasis, 107–8, 109–10, 157–8
 neonatal hepatitis, 147–8, 149, 157–8
 sepsis-associated, 29–30, 246, 730–1
 jejunioleal bypass, cholesterol gallstones in, 266
 JHH. *See* juvenile hereditary hemochromatosis
 JIA. *See* juvenile idiopathic arthritis

Shneider

Index

[More In](#)

Index

- jin bu huan, 364
juvenile hereditary hemochromatosis (JHH)
classification of, 516
clinical features of, 521–2
genetic mutations in, 521–2
physiology and pathophysiology of, 515–16, 517
juvenile idiopathic arthritis (JIA), 739–40
- Kabuki syndrome, 342
kala-azar, 724
kaposiform hemangioendothelioma, 774
Kasai hepatoportoenterostomy
in Alagille syndrome, 237
for biliary atresia, 170, 171, 172, 175
failure, 802
neonatal cholestasis, 110
kava kava, 363–4
Kawasaki disease
gallbladder hydrops in, 256–7
hepatic involvement in, 741
Kayser–Fleischer ring, 490, 491, 499, 500
KDR. *See* kinase insert domain receptor
Kearns Sayre syndrome, 635
kernicterus, 193
Keshan disease, 141
3-ketoacyl-CoA thiolases, 616–17
ketoconazole, 365
2-ketoglutarate dehydrogenase deficiency, 409–11
ketone bodies, in early development, 15–16
kidney. *See also* polycystic kidney disease; renal dysfunction
Alagille syndrome
abnormalities, 231
after liver transplantation, 828
in transferase-deficiency galactosemia, 458
in tyrosinemia, 553, 558, 559–60, 562–3, 565–6
in Wilson disease, 493
KIF12 gene, 29
kinase insert domain receptor (KDR), 4–5
Kupffer cells, 352–3
hepatic immunology, 45
- labor induction, neonatal jaundice, 191
lactate dehydrogenase (LDH), 96
lactate:pyruvate (L:P) ratio, 407–9
mitochondrial hepatopathies, 41–2, 643–4
lactic acidemias, 407–11
lactic acidosis
glycogen storage diseases, 470
mitochondrial hepatopathies, 41–2, 643–4
lactulose, in HE, 50, 71
lamivudine
for HBV infection, 153, 296, 297
hepatotoxicity, 642
lamotrigine, 365
LAP. *See* leucine aminopeptidase
LARS mutations, 41–2
L-asparaginase, 358–9
latent infection, HBV, 293
LC-1. *See* liver cytosol type 1 antibody
LCAD. *See* long-chain acyl-CoA dehydrogenase
L-carnitine supplementation, 622–3
LCHAD. *See* long-chain 3-hydroxyacyl-CoA dehydrogenase
LDH. *See* lactate dehydrogenase
LDLT. *See* living-donor liver transplant
leaky gut hypothesis, 334
ledipasvir–sofosbuvir (Harvoni), 153, 310
Leipzig Scoring System, Wilson disease, 501, 502
leishmaniasis, 724
lenticular changes, in galactosemia, 458–9, 461
leptospirosis, 718, 719
acalculous cholecystitis in, 258
leucine aminopeptidase (LAP), 98
leukemia, 735–6, 774, 775
LFTs. *See* liver function tests
LGR5-positive hepatoblasts, 5
limit dextrinosis. *See* glycogen storage disease, type III
linoleic acid, for cholestasis, 132–3
linolenic acid, for cholestasis, 132–3
LIPA defects. *See* liposomal acid lipase defects
lipase replacement therapy, in CF-associated liver disease, 450
lipid emulsions
in IFALD pathogenesis, 247–9
modifications to treat IFALD, 250–1
lipids
LFTs, 99
metabolism, 15–16
in NAFLD/NASH pathogenesis, 656
lipodystrophy, 659
lipoproteins, LFTs, 99
liposomal acid lipase (LIPA) defects, 406
Liposyn II, 247–9
lipotoxicity, 656
lisdexamfetamine, 361
Listeria monocytogenes, 149, 715
lith genes, 267
lithotripsy, 269–70
liver abscess
amoebic, 719–20
neonatal hepatitis, 149
pyogenic, 710–12
liver cell adenoma. *See* hepatocellular adenoma
liver cell dysplasia, tyrosinemia, 559
liver cytosol type 1 antibody (LC-1), in AIH, 322
liver development, 1
functional
amino acid metabolism, 14–15
bile formation during, 21–3
biotransformation, 16–19
carbohydrate metabolism, 12–14
enzymatic activity in, 12
hepatic energy metabolism, 12
hepatobiliary function during, 19–21
lipid metabolism, 15–16
hepatogenesis, 1, 2
ductal plate malformation, 9
fibrocystic liver disease and, 749, 750
hepatoblast differentiation, 5–7
inductive signaling sources, 1–5
intrahepatic bile duct development, 7–9
specification, 1–5
transcription factors, 5–7
liver disease. *See specific topics*
liver failure. *See also* acute liver failure; fulminant liver failure; Pediatric End-Stage Liver Disease
in HBV infection, 290, 299
in IAH, 323, 324, 329
in PSC, 339–40
tyrosinemia, 553
liver flukes
Clonorchis sinensis, 722–4
Fasciola hepatica, 724
liver function tests (LFTs), 94, 102
categories, 94, 95
clinical interpretation, 94
enzymes detecting impaired bile flow or cholestasis
AP, 96–7
GGT, 97
LAP, 98
5'NT, 97
GWAS, 102
plasma and urine amino acids, 102
reference intervals, 94
sensitivity and specificity, 94–5
serum globulins, 101–2
substances cleared from plasma by liver
ammonia, 100–1
quantitative tests, 101
substances metabolized and transported by liver
bile acids, 100
bilirubin, 99–100
urobilinogen, 100
substances released from injured liver
aminotransferases, 95–6
LDH, 96
synthetic function tests
albumin, 98
for coagulation disorders, 98–9
lipids and lipoproteins, 99
liver regeneration
in ALF, 46
in α_1 -AT deficiency, 430–1
cirrhosis pathophysiology, 59–61
liver stiffness, 82–3
liver transplantation (LTx), 801, 812
acute intermittent porphyria, 537–8
AIH, 330, 825–6
Alagille syndrome, 224, 227, 232, 237–8
ALF, 36–7, 53, 372, 804
alternative procedures, 811
 α_1 -AT deficiency, 419, 431, 802–3
biliary atresia, 174–5, 802, 811–12
outcome, 175–6
as primary therapy, 175
CF-associated liver disease, 450–1, 805
CHF, 754
cholestasis, 116, 802
cirrhosis, 66
contraindications, 802
donor organ options and graft selection, 807–8, 809
deceased donor assessment, 809–10, 811
graft selection and size, 808–9
living donor evaluation, 810
donor organs procurement, 810–11
drug hepatotoxicity, 372
GALD, 527, 803
Gaucher disease, 576
glycogen storage disease
type IA, 472
type IV, 475
in HCV, 313
hepatic tumors, 795, 804–5
hepatic-based metabolic disease, 802–3
in HIV infection, 390
HLH, 393
hyper-IgM syndrome, 387
IFALD, 252

- immune manipulation for, 394–5
immunization before, 143, 801–2
indications, 802–5
long-term outcomes, 830
 chronic comorbidities, 828
 growth and development, 828–30
 patient and graft survival, 826–8
 retransplantation, 805, 812, 828
mitochondrial hepatopathies, 635, 647, 804
NAFLD/NASH, 667–8
peroxisomal disorders, 690
post-transplant care, 816, 830
 early postoperative management, 816–17
 graft dysfunction, 330, 812, 818, 821–6
 immunosuppression, 817–19, 828
 infectious complications, 816–17, 819–21
 primary liver disease, 802–5
 prioritization and allocation
 alternative transplant procedures, 811
 criteria to list patients, 807
 donor liver procurement, 810–11
 donor organ options and graft selection, 807–10, 811
 ethical issues, 811
 scoring systems, 804, 805–7
 waiting list outcomes, 807, 808
PSC, 342
retransplantation, 805, 812, 828
technical aspects, 811–12
transplant evaluation, 801–2
tyrosinemia, 553–4, 563, 564–5, 566, 803
waiting list outcomes, 807, 808
Wilson disease, 505–6
liver tumors. *See* tumors of liver
liver–kidney microsomal (LKM) antibody
 in AIH, 322
 in ALF, 40
 in drug-induced hepatitis, 351–2
living-donor liver transplant (LDLT), 807–8, 809
 in Alagille syndrome, 237–8
 evaluation, 810
LKM antibody. *See* liver–kidney microsomal antibody
long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD), 618
long-chain acyl-CoA dehydrogenase (LCAD), 614–15
loop diuretics, for ascites, 68
losartan, 60
low birth weight, HB association with, 770
L:P ratio. *See* lactate:pyruvate ratio
LTx. *See* liver transplantation
Lucey-Driscoll syndrome, 192
Ludwig score, PSC, 338, 339
Lumacaftor, 451
lumirubin, 193, 194
lung disease, in α_1 -AT deficiency, 417–18, 420–1
lupus erythematosus, 740
 AIH compared with, 321
 neonatal, 156
Lyme disease, 717–18
lymphedema, hereditary
 cholestasis with, 216
lymphoma, 735–6
lysine protein intolerance, 388, 392
lysophosphatidic acid, 124
lysosomal acid lipase deficiency, 586–7
lysosomal storage diseases. *See also* glycoprotein degradation disorders; mucopolysaccharidoses; sphingolipidoses
 in ALF, 41–2
 classification of, 570, 572–3
 laboratory diagnosis, 406–7
 liver in, 570
 mucopolysaccharidosis types II and III, 589–90
 multiple sulfatase deficiency, 590
 treatment for, 570
lysosomes, 570, 571
ma huang, 364
macitentan, 360
macrolide antibiotics, 361–2
macrophage activation syndrome, 391–2
macrotrabecular HB, 778–9, 786
MAdCAM-1. *See* mucosal addressin-cell adhesion molecule 1
magnesium, for cholestasis, 140–1
magnetic resonance cholangiopancreatogram (MRCP)
 in AIH, 324
 liver complications in immunodeficiency, 384, 386
 PSC, 336–8
magnetic resonance imaging (MRI)
 GALD-NH, 526
 hepatic tumors in, 774, 775
mitochondrial hepatopathies, 644
NAFLD/NASH, 660–1
secondary iron overload, 522
tyrosinemia, 558
Wilson disease, 499
Majoie classification, PSC, 336–8
malabsorption
 in Alagille syndrome, 231, 237
 cholestasis
 hepatic osteodystrophy, 130
 nutritional assessment, 130
 nutritional management guidelines, 131
 nutritional therapy, 130–42
 steatorrhea, malnutrition, and growth failure, 129–30
 fructose, 466
 malaria, 724–5
 maleylacetoacetate, 548–9
 malignancy. *See also* tumors of liver
 in α_1 -AT deficiency, 430–1
 in choledochal cysts, 179
 immunodeficiency-associated, 386–7
 Wilson disease, 492
malignant hepatocellular neoplasm, not otherwise specified (HCN-NOS), 778–9, 786
malignant rhabdoid tumor (MRT), 777–8
malnutrition. *See also* nutritional therapy
 in Alagille syndrome, 231, 237
 in cholestasis, 129–30
 in chronic liver disease, 71–2
 cirrhosis, 64, 71–2
 hepatic involvement in, 742
malonyl-CoA, 611, 613
malpositioned gallbladders, 256
manganese
 for cholestasis, 141–2
 in IFALD pathogenesis, 249
manganese retention disorder, 511
mannose therapy, for phosphomannose isomerase deficiency, 477
 α -mannosidosis, 582
maple syrup urine disease (MSUD), 414–15
maternal diabetes, neonatal jaundice, 192
maternal screening, for HBV markers, 298
matrix metalloproteinase-7 (MMP-7), 168
matrix metalloproteinase (MMP), neonatal cholestasis, 113–14
Mavret. *See* glecaprevir/pibrentasvir
MCAD. *See* medium-chain acyl-CoA dehydrogenase
MCT oil, for cholestasis, 132
MDMA. *See* 3,4-methylenedioxymethamphetamine
MDR1 gene
 in early development, 19
 in HB, 796
MDR3. *See* multidrug resistance-associated protein 3; progressive familial intrahepatic cholestasis type 3
mechanical ventilation, hepatic dysfunction in, 730
meclizine, 796
meconium ileus, in CF, 442
medium-chain 3-ketoacyl-CoA thiolase, 616, 619
medium-chain acyl-CoA dehydrogenase (MCAD), 615, 618–19
MEDNIK syndrome, 511
MEGDHEL, 634, 639
MEGX test. *See* monoethylglycinexylidide test
MELD. *See* Model for End-Stage Liver Disease
menadione, for cholestasis, 139–40
menaquinone, for cholestasis, 139–40
Menkes disease, 489
meperidine, pruritus with, 124
mephenytoin, hepatic metabolism, 349
Mephyton, 139–40
6-mercaptopurine
 for AIH, 327–8
 hepatic metabolism, 349–50
 hepatotoxicity, 358–9, 360
mercury poisoning, 357
mesenchymal hamartoma
 acquired genetic abnormalities in, 790
 AFP levels, 774
 clinical presentation, 775
 pathology, 780–1, 792
meso-Rex bypass, 89, 824
metabolic disorders. *See also* inborn errors of metabolism
 Alagille syndrome with, 228
 ALF, 41–2, 51–2
 cholestasis with, 130
 cirrhosis, 62
 Wilson disease, 494
metabolic syndrome
 fetal energy metabolism role in, 12
 NAFLD/NASH association with, 654–5, 657, 659–60
metallochaperones, 486
metallothionein, 484, 485
metformin, 666–7
methotrexate
 hepatotoxicity, 365–6
 for PSC, 341–2
 α -methylacyl-CoA racemase (AMACR) deficiency, 603–4, 684–5

Shneider

Index

[More In](#) Index

- 3,4-methylenedioxy
methamphetamine
(MDMA), 361
- methylprednisolone, for
cholestasis, 121–2
- metronidazole, in HE, 71
- MICOS. *See* mitochondrial con-
tact site and cristae orga-
nizing system
- microbiome
in CF, 441, 451
in PSC development, 334
- microRNAs
in CF-associated liver disease,
449
in HB, 792
- Microsporidia* species
in HIV cholangiopathy,
389–90
in sclerosing cholangitis, 386
- microvillus inclusion disease
(MVID), 217
- microwave ablation therapy, for
hepatic tumors, 796
- midodrine, for HRS, 70
- milk of calcium bile, 260–1
- minocycline
autoimmune-like hepatitis
with, 324, 351–2
hepatotoxicity, 366
- mitochondria
damage in NAFLD/NASH,
656–7
dysfunction in drug
hepatotoxicity, 350, 371
functions, 629–31
respiratory chain protein
complexes, 628–30
structure and genetics, 628–9
- mitochondrial contact site
and cristae organizing
system (MICOS), 634,
639
- mitochondrial depletion
syndromes
laboratory diagnosis, 405–6
neonatal hepatitis, 524
- mitochondrial hepatopathies,
628, 648–9
in ALF, 41–2
canonical clinical syndromes,
632
classification, 632–3, 634
diagnosis
biochemical tests, 41–2,
643–4
clinical features and
diagnostic approach, 643
enzymatic and functional
assays, 645–6
genetic testing, 643, 644,
645, 648
histopathological
investigations, 630, 631,
633–6, 646
MRI, 644
epidemiology, 631–2
GALD-NH, 526
- genetic etiologies, 631–2,
634
primary/mtDNA deletions,
633–5, 639–40
BCS1 L, 634, 639
DGUOK, 634, 638
GFM1, 634, 639
MPV17, 634, 637
POLG, 634, 635–7
QILI, 634, 639
SERAC1, 634, 639
SUCLG1, 634, 638
TRMU, 634, 639
TWNK, 634, 638
TYMP, 634, 637–8
- secondary, 633, 640
drugs and toxins,
641–2, 646
hydrophobic bile acid
toxicity, 642
NAFLD/NASH, 642–3
Reye syndrome, 640, 641
Wilson disease, 640–1
- systemic presentations,
628
- treatment, 646
diet, 646–7
gene and cell-based therapy,
648
liver transplantation, 635,
647, 804
pharmacologic support,
646, 647
prenatal diagnosis, 648
- mitochondrial
neurogastrointestinal
encephalomyopathy
(MNGIE), 634, 637–8
- mitogen-activated protein kinase
pathway signaling, in HB,
786
- mixed connective tissue disease,
740
- MMP. *See* matrix
metalloproteinase
- MMP-7. *See* matrix
metalloproteinase-7
- MNGIE. *See* mitochondrial neu-
rogastrointestinal
encephalomyopathy
- Model for End-Stage Liver
Disease (MELD)
cirrhosis, 66
transplantation prioritization
and allocation, 806–7
- molecular adsorbent
recirculating system, for
ALF, 52
- molecular chaperones, for
cholestasis, 123
- monoethylglycinexylidide
(MEGX) test, 101
- morphine, gallbladder
sludge development with,
264
- morphogenesis defect, biliary
atresia cause and
pathogenesis, 166
- mother-to-infant
transmission
HBV
intrauterine, 289
perinatal, 285, 287–9
HCV, 306, 313
- moxalactam, neonatal jaundice
with, 192
- moyamoya disease, 226–7
- MPI* mutations, 477
- MPI*-CDG. *See* phosphomannose
isomerase deficiency
- MPSs. *See*
mucopolysaccharidoses
- MPV17* deletions, 634, 637
- MRCP. *See* magnetic resonance
cholangiopancreatogram
- MRI. *See* magnetic resonance
imaging
- MRP2. *See* multidrug resistance-
associated protein 2
- MRT. *See* malignant rhabdoid
tumor
- MSUD. *See* maple syrup urine
disease
- mucins
in CF, 441
gallbladder, 265
- mucopolipidosis types II and III,
589–90
- mucopolysaccharidoses (MPSs)
clinical features, 587–9
diagnosis, 589
genetics, 587
treatment, 589
- mucosal addressin-cell
adhesion molecule 1
(MAdCAM-1), 334–5
- multidrug resistance, in HB, 796
- multidrug resistance-associated
protein 2 (MRP2), 27, 201
- multidrug resistance-associated
protein 3 (MDR3), 27
- multilobular cirrhosis, in CF,
444–5, 449–50
- multinucleated giant cells,
neonatal hepatitis, 158
- multiple sulfatase deficiency, 590
- mushroom ingestion, 39
- mutant α_1 -antitrypsin Z, 417–18
autophagy enhancer drugs for,
431–2
cellular adaptive responses to,
425–8
chemical chaperones for,
432–3
gene therapy for, 432
structure-based screening
strategies for, 432
- mutation analysis, Alagille
syndrome, 234
- MVD, 676–7
- MVID. *See* microvillus inclusion
disease
- MVK, 676–7
- mycobacterial infections
Mycobacterium avium
complex, 716–17
- HIV coinfection,
156
sclerosing cholangitis, 386
tuberculosis, 149, 715–16
- mycophenolate mofetil
for AIH, 328
for post-liver transplant AIH,
330
post-transplant, 817–18
for PSC, 341–2
- MYO5B* mutations, 217
- myofibroblasts, cirrhosis
pathophysiology, 59–60
- myrcludex, 27
- myrcludex B, for cholestasis, 122
- MZ phenotype, α_1 -AT
deficiency, 419
- N*-acetylcysteine
for acetaminophen
hepatotoxicity, 38, 355–6,
357, 372
for IFALD, 252
- N*-acetylglutamate synthase
(NAGS) deficiency,
413–14
- N*-acetyltransferases, 18, 349–50
- Na*-dependent taurocholate
cotransporting
polypeptide (NTCP)
in bile formation and flow,
26–7, 28
inhibitors, 122, 123
- NADH-CoQ reductase, 628–30
- NAFLD/NASH. *See* non-alco-
holic fatty liver disease/
non-alcoholic
steatohepatitis
- NAGS deficiency. *See* *N*-acetyl-
glutamate synthase
deficiency
- NAIC. *See* North American
Indian cholestasis
- Nakanuma stage, PSC, 339
- Na^+/K^+ -ATPase, in early
development, 21
- nalmefene, for pruritus of
cholestasis, 124, 125–6
- naloxone, for pruritus of
cholestasis, 124, 125–6
- naltrexone
for cholestasis, 119, 125–6
for pruritus of cholestasis, 124,
236
- naproxen, 367
- nasobiliary drainage, for pruritus
of cholestasis, 127
- natural killer (NK) cells, hepatic
immunology, 45
- Navajo neurohepatopathy
(NNH), 634, 637
- NBAS deficiency, 41–2
- NEC. *See* necrotizing
enterocolitis
- necrosis, in ALF, 46–7, 48
- necrotizing enterocolitis (NEC),
246–7
- neomycin, in HE, 50, 71

Shneider

Index

[More I](#)

Index

- neonatal cholestasis
bile ductular paucity, 109
in CF, 444
clinical presentation, 157–8
definition, 107
differential diagnosis, 107–9,
157
evaluation
 general approach, 110–12
 genetic evaluation, 113
 histopathological
 evaluation, 112–13
 laboratory, urine and stool
 assessment, 112
 radiologic assessment, 112
immature hepatic excretory
 function in, 23
incidence, 107
jaundice, 107–8, 109–10,
157–8
management, 116–18
manifestations, 109–10
physiologic, 30
screening, 113–14
treatable causes, 117
- neonatal hemochromatosis
(NH), 394. *See also* gesta-
tional alloimmune liver
disease
in ALF etiology, 40–1
classification of, 523
diagnosis of, 525–6
etiology and pathogenesis of,
523–4
laboratory diagnosis, 406
liver transplantation,
527, 803
medical therapy for, 527
pathology of, 524–5
preventive therapy for, 527
- neonatal hepatitis
Alagille syndrome, 224–5
chromosomal disorders,
156–7
clinical presentation, 157–8
congenital infections, 147
 bacterial, 147–9
 histopathology, 147, 148
 parasitic, 150
 routes of, 147
 viral, 150–6
Coombs-positive giant cell,
157
differential diagnosis, 157
familial intrahepatic
 cholestatic syndromes,
157
histopathology, 147, 148, 158
idiopathic, 147, 162
 cholestasis, 107, 108–9
 jaundice, 147–8, 149,
157–8
lupus erythematosus, 156
neonatal cholestasis, 107,
108–9
prognosis, 158–9
pseudo-TORCH syndrome,
157
- neonatal hepatobiliary disease,
162
- neonatal ichthyosis-sclerosing
cholangitis syndrome
(NISCH), 342
- neonatal jaundice, 107–8,
109–10, 157–8, 182
 American Academy of
 Pediatrics management
 guidelines, 189
 assessment approach, 189, 190
 causes overview, 189
 clinical presentation, 187–9
 decreased bilirubin excretion
 breastfeeding, 191–2, 195
 drugs, 192
 hepatic hypoperfusion and
 liver disease, 192
 hormone dysfunctions, 192
 increased bilirubin
 production with, 192–3
 increased enterohepatic
 circulation, 191
 Lucey–Driscoll syndrome,
192
 maternal diabetes, 192
 prematurity, 192
 epidemiologic risk factors, 189
 immature hepatic excretory
 function in, 23
 increased bilirubin production
 decreased bilirubin with,
192–3
 extravascular blood, 191
 isoimmunization, 189–91
 labor induction with
 oxytocin, 191
 polycythemia, 191
 red blood cell abnormalities,
191
 management, 193–5
 toxicity of, 193
- neonatal lupus erythematosus,
156
- neonatal sclerosing cholangitis,
342
- neonate
acetaminophen hepatotoxicity
 in, 357
amino acid metabolism in,
14–15
bile formation in, 21–3
biotransformation in, 16–19
carbohydrate metabolism in,
12–14
enzymatic activity in, 12
hepatic energy metabolism in,
12
hepatobiliary function in,
19–21
lipid metabolism in, 15–16
nested stromal-epithelial tumor
(NSET)
 clinical presentation, 774, 775
 pathology, 779–80, 788
neuroblastoma, 774, 775
neurodevelopment, in Alagille
 syndrome, 231–2
- neurologic symptoms
ALF, 48–50
cirrhosis, 62–3, 70–1
neonatal jaundice, 193
Niemann–Pick disease type C,
580
tyrosinemia, 554–6, 565
Wilson disease, 492–3,
499
- neuromuscular development,
glycogen storage diseases,
474
- neutropenia, glycogen storage
diseases, 472
- nevirapine, 366–7
- newborn screening, IEMs, 402,
415
 galactosemia, 457, 460
 tyrosinemia, 550–1
- next generation sequencing
(NGS), IEM diagnosis,
403–5
- NH. *See* neonatal
 hemochromatosis
- Niemann–Pick disease type C
(NPC)
 in ALF, 41–2
 genetic mutations in, 579,
580–1
 histopathology of, 580
 neurological symptoms with,
580
 subtypes of, 580
 treatment of, 581
- Niemann–Pick types A and B,
576–8
- nifedipine, 349
- nimesulide, 367
- NISCH. *See* neonatal
 ichthyosis-sclerosing
 cholangitis syndrome
- nitazoxanide, 388
- nitisinone, for tyrosinemia, 803
- acute liver crises and, 564
chronic liver disease and,
564–5
diet and, 561
initiation of, 562
- 2-(2-nitro-4-trifluoromethyl
benzoyl)-1,
3-cyclohexanedione
(NTBC), for tyrosinemia,
803
- nitrofurantoin, autoimmune-like
hepatitis with, 324, 351–2
- nitrogen metabolism, 698–9
- nitrosoureas, drug-induced liver
disease, 358–9
- NK cells. *See* natural killer cells
- NKH. *See* non-ketotic
 hyperglycemia
- N-linked glycosylation defects,
475–7
- NNH. *See* Navajo
 neurohepatopathy
- nocturnal feedings, for glycogen
storage diseases, 471–2,
473–4
- nodular regenerative
 hyperplasia, 388
- non-absorbable ion exchange
 resins
 for hyperlipidemia and
 xanthomas in cholestasis,
128
 for pruritus of cholestasis, 125
- non-alcoholic fatty liver disease/
non-alcoholic
 steatohepatitis (NAFLD/
 NASH), 653, 668
clinical diagnostic and
 prognostic tools, 659
anthropometrics, 659–60
biomarkers and panels, 660
imaging, 660–1
liver biopsy, 661–3
 routine laboratory tests, 660
epidemiology, 653–6
fetal energy metabolism role
 in, 12
histopathology, 663–6
in HIV infection, 389
mitochondrial dysfunction in,
642–3
mortality outcomes, 655–6
natural history, 655
pathogenesis, 656
 genetic and environmental
 influences, 657–9
 genetic heterogeneity and
 risk, 657
 lipids and lipotoxicity, 656
 mitochondrial and ER
 stress, 656–7
 nutritional factors, 657
 treatment, 666–8
- non-ketotic hyperglycemia
(NKH), 414–15
- non-steroidal anti-inflammatory
drugs (NSAIDs), 367
- North American Indian
cholestasis (NAIC), 218
- nor-UDCA
 for CF-associated liver disease,
451–2
 for cholestasis, 122, 123
- NOTCH2* mutations, in Alagille
 syndrome, 222, 226, 233,
234
- gene identification and
 mutation analysis, 234
genetic testing, 235–6
genotype–phenotype
 correlations, 235
- Notch signaling pathway
 effects, 9, 234–5
- Notch signaling
 in Alagille syndrome, 9, 234–5
 in HB, 786
 intrahepatic bile duct
 development, 9, 235
- NPC. *See* Niemann–Pick disease
 type C
- NR1H4* mutations, 218. *See also*
 farnesoid X receptor
- NRs. *See* nuclear receptors

Shneider

Index

[More In](#)

Index

- NSAIDs. *See* non-steroidal anti-inflammatory drugs
- NSET. *See* nested stromal-epithelial tumor
- 5'NT. *See* 5'-nucleotidase
- NTBC. *See* 2-(2-nitro-4-trifluoromethyl benzoyl)-1, 3-cyclohexanedione
- NTCP. *See* Na-dependent taurocholate cotransporting polypeptide
- nuclear receptors (NRs)
agonists, 122
in cholestasis pathogenesis, 28–9
in early development, 22–3
xenobiotic, 17
- nucleoside/nucleotide analogues
for HBV infection, 153, 296–7
hepatotoxicity, 642
- 5'-nucleotidase (5'NT), 97
- nutritional disorders, 742. *See also* malnutrition
- celiac disease, 742
- dietary supplements, 363–4, 742–3
- NAFLD/NASH as, 657
- nutritional therapy
for Alagille syndrome, 237
for ALF, 52
for CF-associated liver disease, 450
for cholestasis, 116, 130–2
assessment, 130
calcium and phosphate, 140
copper, manganese, and aluminum, 141–2
EFAs, 132–3
energy, 132
fat, 132
fat-soluble vitamins, 133–40
iron, 141
magnesium, 140–1
management guidelines, 131
protein, 132
selenium, 141
water-soluble vitamins, 140
zinc, 141
cirrhosis, 71–2
- OATP1B* mutations, 200
- obesity
cholesterol gallstones in, 266
fetal energy metabolism role in, 12
liver biopsy risk in, 662–3
NAFLD/NASH association with, 653, 654–5, 657, 659–60
nitisinone treatment and, 563–4
- obeticholic acid (OCA)
for cholestasis, 28–9, 122
for cirrhosis, 60
for PSC, 342
- OBI. *See* occult HBV infection
- OCA. *See* obeticholic acid
- occult HBV infection (OBI), 291, 300
- ocular abnormalities
Alagille syndrome, 229–31
galactosemia, 458–9, 461
Wilson disease
Kayser–Fleischer ring, 490, 491, 499, 500
sunflower cataract, 490–1
- oculocutaneous tyrosinemia, 549, 552
- OKT3 antibodies, 394–5
- O-linked glycosylation defects, 475–7
- omega-3 DHA, 132–3, 689
- Omegaven, 247–9, 250–1
- ONECUT1
in cholangiocyte differentiation, 5
in intrahepatic bile duct development, 8–9
- ONECUT2, in intrahepatic bile duct development, 8–9
- opiate receptor system, pruritus pathogenesis, 124
- opioid antagonists, for pruritus of cholestasis, 124, 125–6, 236
- opportunistic infections
in HIV cholangiopathy, 389–90
in sclerosing cholangitis, 384–7
management, 387–8
- optic disk drusen, Axenfeld anomaly, 231
- OPTN. *See* Organ Procurement and Transplantation Network
- oral antiviral agents, for HBV infection, 153, 296–7
- oral contraceptives
gallstones associated with, 265, 267
hepatotoxicity, 362
- Organ Procurement and Transplantation Network (OPTN), 805–7
- organic acidurias
laboratory diagnosis, 407
liver transplantation, 802–3
newborn screening, 415
- organs, donor. *See* donor organs
- ornithine transcarbamylase (OTC) deficiency
laboratory diagnosis, 413–14
urea cycle disorders, 701
- osteo-oto-hepato-enteric syndrome, 217
- osteoporosis
Alagille syndrome with, 228
in galactosemia, 461
- OTC deficiency. *See* ornithine transcarbamylase deficiency
- outflow obstruction
in ALF, 45–6
after liver transplantation, 824–5
- ovarian failure, in transferase-deficiency galactosemia, 459, 461
- oxacillin, 367
- oxaliplatin
drug-induced liver disease, 358–9
for hepatic tumors, 795
- oxidation, peroxisome, 673–6
- oxidative phosphorylation (OXPHOS), 628–31. *See also* mitochondrial hepatopathies
- oxidative stress
in copper toxicity, 487
in mitochondria, 629–30
in NAFLD/NASH, 656–7
- oxoprolinemia, 349–50, 357
- Δ^4 -3-oxosteroid 5 β -reductase (AKR1D1) deficiency, 602
- neonatal hepatitis, 524
- UDCA therapy, 121
- OXPHOS. *See* oxidative phosphorylation
- oxysterol 7 α -hydroxylase (CYP7B1) deficiency, 600
- oxytocin, neonatal jaundice, 191
- p16, 786–7
- p27, 786–7
- p53, 787–8
- PABA) test. *See* para-aminobenzoic acid
- PALFSG. *See* Pediatric Acute Liver Failure Study Group
- pANCA. *See* perinuclear anti-neutrophil cytoplasmic antibody
- pancreas, tyrosinemia, 558, 560
- pancreatic enzyme replacement therapy, in CF-associated liver disease, 450
- pancreatic insufficiency, Wilson disease, 494
- pancreatitis, ALF complications and management, 51
- pancuronium, 192
- para-aminobenzoic acid (PABA) test, 101
- paramyxovirus infections
ALF in, 42–3
neonatal hepatitis, 155
- parasitic infections
acalculous cholecystitis in, 258
Ascaris lumbricoides, 264, 721
capillariasis, 722
echinococcal disease, 720–1
Entamoeba histolytica, 719–20
- gallstones associated with, 264
in HIV cholangiopathy, 389–90
leishmaniasis, 724
liver flukes
Clonorchis sinensis, 722–4
Fasciola hepatica, 724
malaria, 724–5
schistosomiasis, 722, 723
in sclerosing cholangitis, 384–7
management, 387–8
toxocarriasis, 721–2
toxoplasmosis, 150
- parenteral nutrition (PN)
amino acid component, 247
cholestasis associated with, 242, 243–4
fatty acid role in, 247–9
pathogenesis, 30
UDCA therapy, 121
- excessive energy or carbohydrate load, 247
- lipid emulsions, 247–9
- liver disease associated with, 242
clinical presentation and natural history, 242–3
histology, 243–4
risk factors and pathogenesis, 244–9
treatment, 250–2
- modifications to treat IFALD
lipid factors, 250–1
non-lipid factors, 250
- paromomycin
cryptosporidiosis
management, 388
for HIV cholangiopathy, 389–90
- pars cystica, 255
- pars hepatica, 255
- partial biliary diversion
for Alagille syndrome, 236–7
for pruritus of cholestasis, 127
- parvovirus hepatitis
ALF in, 42–3
neonatal hepatitis, 155
- passive immunization
HAV, 276
HBV, 298
- PBD-ZSD. *See* peroxisome biogenesis disorders-Zellweger spectrum disorders
- PBG. *See* porphobilinogen
- PCT. *See* porphyria cutanea tarda
- PDS. *See* primitive ductal structures
- Pearson marrow-pancreas syndrome, 634, 635
- PECR, 673–6
- pediatric acute liver failure. *See* acute liver failure
- Pediatric Acute Liver Failure Study Group (PALFSG)
entry criteria, 36, 37

Shneider

Index

[More I](#)

Index

- etiologies of ALF in, 37–8
outcomes, 53
Pediatric End-Stage Liver Disease (PELD)
cirrhosis, 66
transplantation prioritization and allocation, 806–7
Pediatric Hepatic malignancy International Therapeutic Trial (PHITT), 769
chemotherapy, 795
liver transplantation, 795
surgical tumor removal, 793–4
pegasparase, 358–9
pegylated interferon
for HBV infection, 296
for HCV infection, 153, 310, 312
for HEV infection, 281
PELD. *See* Pediatric End-Stage Liver Disease
pembrolizumab, 388
pemoline, 367
penicillin
for congenital syphilis, 149
hepatotoxicity, 367
Penicillium marneffei, 725
4-pentenoic acid, 370, 371
PEPCK. *See* phosphoenolpyruvate carboxykinase
perforin deficiency, 392, 393
perihepatitis, bacterial, 713
perinatal infection, 147
perinatal transmission
HBV, 285, 287–9
HCV, 306, 313
perinuclear anti-neutrophil cytoplasmic antibody (pANCA), in AIH, 322
peripheral nerve, tyrosinemia, 560
peroxide degradation, 674, 678
peroxisomal disorders, 605–6, 671. *See also* peroxisome biogenesis disorders-Zellweger spectrum disorders
hepatic disease mechanisms, 687–8
laboratory evaluation and molecular diagnostic tools, 675, 678–9
management
bile acid supplementation, 689–90
clinical symptom, 688–9
DHA supplementation, 689
liver transplantation, 690
phytanic acid-restricted diet, 689
therapies under development, 690
mouse models
single protein/enzyme deficiencies, 686–7
Zellweger spectrum disorder models, 685–6
patient presentation, 690
adolescence and adulthood, 690
childhood, 690
infancy, 683, 690
single protein/enzyme deficiencies
ABCD3 deficiency, 604–5, 683–4
ACOX1 deficiency, 684
ACOX2 deficiency, 684
AMACR deficiency, 684–5
BAAT deficiency, 685
DBP deficiency, 684
peroxisome
biogenesis, 672
general aspects, 671–2
metabolic pathways, 673, 675
alpha-oxidation, 674, 676
amino acid metabolism, 674, 677–8
beta-oxidation, 673–6
bile acid synthesis, 674, 676–7
biochemical assays of, 675, 678–9
ether lipid biosynthesis, 674, 677
peroxide degradation, 674, 678
pristanic and bile acid racemization, 674, 677
peroxisome biogenesis disorders-Zellweger spectrum disorders (PBD-ZSD), 672, 679
clinical manifestations
intermediate and milder disease, 679–80
severe disease, 679
liver disease evolutions and liver histology in, 680–2
liver ultrastructure, 682–3
mouse models, 685–6
patient presentation, 690
adolescence and adulthood, 690
childhood, 690
infancy, 683, 690
peroxisome proliferator-activating receptor (PPAR), 611–13
PET. *See* positron emission tomography
Peutz-Jegher syndrome, 260
PEX genes, 671, 672, 679
PEX proteins, 672
PFIC. *See* progressive familial intrahepatic cholestasis
PGM1 mutations, 477
PGM1-CDG. *See* phosphoglucomutase deficiency
PH1. *See* primary hyperoxaluria type 1
phenobarbital
for cholestasis, 121, 126
hepatic metabolism, 350
hepatotoxicity, 367–8, 646
in utero therapy, 195
4-phenyl butyrate
for α_1 -AT deficiency, 432–3
for cholestasis, 123
phenylalaninyl-tRNA synthetase deficiency, 639–40
phenylketonuria, 552
phenytoin
hepatic metabolism, 350
hepatotoxicity, 368
PHITT. *See* Pediatric Hepatic malignancy International Therapeutic Trial
phlebotomy
for HH, 521
for JHH, 522
for PCT, 539–40
phosphate, for cholestasis, 140
phosphoenolpyruvate carboxykinase (PEPCK), 13–14
phosphoglucomutase deficiency (PGM1-CDG), 477
phospholipids, in bile, 264–6
phosphomannomutase deficiency (PMM2-CDG), 477
phosphomannose isomerase deficiency (MPI-CDG), 477
phosphotransferase, 589
phototherapy, for neonatal jaundice, 193–4
PHYH, 676
phyloquinone, for cholestasis, 139–40
physiologic cholestasis of newborn, 30
physiologic jaundice, 187, 189
phytanic acid-restricted diet, peroxisomal disorders, 689
phytosterols, in IFALD pathogenesis, 247–9
PIDs. *See* primary immunodeficiencies
pigment gallstones, 261–3
conditions predisposing to black
chronic hemolytic disease, 263, 270
cirrhosis and chronic cholestasis, 264
miscellaneous, 264
TPN-related, 263–4
conditions predisposing to brown, 264
Pima Indians, gallstones in, 265–6
PiM_{malton} phenotype, α_1 -AT deficiency, 419
pioglitazone, 666–7
PIPOX, 677–8
piroxicam, 367
PiSZ phenotype, α_1 -AT deficiency, 419
PiZZ α_1 -AT deficiency, 417–18
liver disease in, 418–19, 420
lung disease, 420–1
mechanism for, 424–5, 426
treatment, 431–3
PKD. *See* polycystic kidney disease
PKD1L1 gene, 29
PKD mutations, 759–60, 762–5
PKHD1 mutations, 750, 752–4, 755–6, 762–5
PLA. *See* pyogenic liver abscess
plasma amino acids, 102
plasmapheresis/plasma exchange, for ALF, 52
Plasmodium infection, 724–5
platelet dysfunction, glycogen storage diseases
type IA, 471
type IB, 472
PLD. *See* polycystic liver disease
pleconaril, 155
PMM2 mutations, 477
PMM2-CDG. *See* phosphomannomutase deficiency
PMVK, 676–7
PN. *See* parenteral nutrition
pneumococcal infection, 715
Pneumocystis jirovecii infection, post-transplant, 820–1
PNPLA3 mutations, 657
polarographic testing, mitochondrial hepatopathies, 645
POLG deletions in, 634, 635–7
polio vaccine, 143
polyarteritis nodosa, gallbladder inflammation in, 260
polycystic kidney disease (PKD) autosomal dominant, 759–60
autosomal recessive, 750, 751, 755–6, 757
pathogenesis and animal models, 762–5
polycystic liver disease (PLD), 761–2
polycythemia, neonatal jaundice, 191
polygonum multiflorum, hepatotoxicity, 364
polyp, gallbladder, 260
polysplenia syndrome, 110
biliary atresia with, 162, 163
Pompe disease. *See* glycogen storage diseases, type II
porcelain gallbladder, 260–1
porphobilinogen (PBG), 530
porphyria cutanea tarda (PCT), 530, 533
clinical features of, 539
development of, 538–9
diagnosis of, 539
treatment of, 539–40
porphyrias. *See also specific porphyrias*
animal models of, 544
classification of, 533–4
cutaneous, 534
diagnosis of, 534

Shneider

Index

[More In](#)

Index

- porphyrias (cont.)
 dual, 544
 erythropoietic, 530, 533–4, 542
 heme biosynthesis and, 530
 hepatic, 530, 533, 534
 subclinical, 534
- portal hypertension
 Alagille syndrome, 223–4
 in ARPKD, 755–6
 α_1 -AT deficiency, 418
 capillary role in, 74
 in CF, 450–1
 in CHF, 752–4, 755
 in cirrhosis, 59
 clinical features, 61
 clinical manifestations, 74–5, 79–80
 definition, 74
 diagnostic evaluations, 82
 angiography, 83
 endoscopy, 83, 84–5, 86
 HVP, 83
 ultrasonography, 82
 experimental models, 75
 in IAH, 324
 in immunodeficiency, 388
 natural history, 81
 biliary atresia, 81
 EHPVO, 81
 pathophysiology, 75–6
 increased vascular resistance, 76–8
 systemic vasodilation, 78–9
 pediatric disorders associated with, 74
 signs and symptoms, 74–5
 therapy, 83–4, 89–90
 emergency variceal hemorrhage, 84–5, 86–7
 pre-primary prophylaxis, 84
 primary prophylaxis, 84
 screening, 89–90
 secondary prophylaxis, 87–9
- portal vein (PV), reconstruction, 812
- portal vein thrombosis (PVT), after liver transplantation, 823–4
- portosystemic shunting
 in CF, 450–1
 in portal hypertension, 74–5, 88–9
- positron emission tomography (PET), Wilson disease, 499
- posterior embryotoxon, in Alagille syndrome, 229–31
- postnatal infection, 147
- post-transfusion hepatitis, 154
- post-transplant care, 816, 830
 early postoperative management, 816–17
 graft dysfunction, 330, 812, 818, 821–6
 immunosuppression, 817–19, 828
- infectious complications, 816–17, 819–21
- PPAR. *See* peroxisome proliferator-activating receptor
- PPAR α receptor agonists, for cholestasis, 122, 123
- precision medicine, drug-induced liver disease prevention, 372
- precure mutations, HBV, 290, 293
- prednisolone, for AIH, 327–8
- prednisone
 for AIH, 327–8
 for drug-induced liver disease, 372
- pregnancy
 cholesterol gallstones in, 267
 FAO disorders and, 624
 tyrosinemia and, 562
 Wilson disease treatment in, 506–7
- pregnane X receptor (PXR)
 agonists, 122
 in cholestasis pathogenesis, 28–9
 in early development, 17
 in gallstone formation, 267
- prematurity
 HB association with, 770
 in IFALD pathogenesis, 245–6
 neonatal jaundice, 192
- prenatal genetic testing
 for Alagille syndrome, 236
 mitochondrial hepatopathies, 648
 for tyrosinemia, 552
- pretreatment extent of disease (PRETEXT) staging system, 775–6, 777, 778, 779
- primary endocrine neoplasms, 774, 775
- primary hyperoxaluria type 1 (PH1), 671
- primary immunodeficiencies (PIDs). *See also* hemophagocytic lymphohistiocytosis
 in ALF, 40
 chronic granulomatous disease, 394
 common, 384, 385
 HBV infection in, 390–1
 HCV infection in, 391
 sclerosing cholangitis in, 386, 387
 management, 387–8
 opportunistic infection in, 384–8
 XLP disease, 393–4
- primary sclerosing cholangitis (PSC), 333, 342–3
 AIH overlap syndrome, 324, 326, 329, 333, 340, 341–2
 clinical features and diagnosis, 335–6
- auto-antibodies, 336
 histology, 338–9
 IBD relationship, 336
 imaging, 336–8
 laboratory findings, 336
- epidemiology, 333
 IBD relationship with, 333, 334, 336, 339–40
- liver transplantation in, 342
- management, 340
 immunosuppression, 341–2
 obeticholic acid, 342
 simtuzumab, 342
 UDCA, 340–1
 vancomycin, 341
- pathogenesis, 333
 cholangiocyte injury, 335
 environmental factors, 334
 genetics, 333–4
 immune mediated, 334–5
 prognosis, 339–40
 UDCA therapy, 120
- primitive ductal structures (PDS), 7, 8
- pristanic acids, peroxisome racemization of, 674, 677
- PRKCSH mutations, 761–2
- progressive familial intrahepatic cholestasis (PFIC)
 genes, 109
 hepatic tumors in, 771, 773
 UDCA therapy, 120
- progressive familial intrahepatic cholestasis type 1 (PFIC1, ATP8B1), 204
 clinical features, 204–6
 genetics, 207
 histopathology, 206–7
 laboratory diagnosis, 406
 laboratory findings, 206
 pathophysiology, 207–8
 treatment, 211–12
- progressive familial intrahepatic cholestasis type 2 (PFIC2, ABCB11), 208–9
 clinical features, 209
 genetics, 210
 histopathology, 209
 laboratory findings, 209
 pathophysiology, 210–11
 treatment, 211–12
- progressive familial intrahepatic cholestasis type 3 (PFIC3, ABCB4), 212
 clinical features, 213
 genetics, 214–15
 histopathology, 214
 laboratory studies, 213
 pathophysiology, 215
 treatment, 215–16
- progressive lenticular degeneration. *See* Wilson disease
- pro-inflammatory mechanisms, biliary atresia cause and pathogenesis, 166–7
- propionic acidemia, in immunodeficiency, 388
- propranolol, for portal hypertension, 84
- propylthiouracil, 368–9
- protein intake, cholestasis, 132
- prothrombin time (PT)
 test description, 98–9
 vitamin K status, 140
- PROTO-oxidase, 541
- protoporphyrin, 542
- protozoan infections, neonatal hepatitis, 150
- PROX1, in hepatocyte differentiation, 5
- pruritus
 in Alagille syndrome, 222–3, 232, 236–8
 of cholestasis, 124
 pathogenesis, 124–5
 treatment, 125–7, 236
- PSC. *See* primary sclerosing cholangitis
- pseudoparkinsonian, Wilson disease, 492–3
- pseudosclerosis, Wilson disease, 492–3
- pseudo-TORCH syndrome, neonatal hepatitis, 157
- psychiatric symptoms, Wilson disease, 492–3, 499
- PT. *See* prothrombin time
- public health
 HAV implications, 278
 NAFLD/NASH implications, 653
- pulmonary artery anomalies, in Alagille syndrome, 225–6
- pulmonary artery hypertension
 cirrhosis, 62
 portal hypertension, 80
- pulmonary edema, ALF, 52
- pulmonary manifestations
 ALF, 52
 cirrhosis, 62
 portal hypertension, 79–80
- PV. *See* portal vein
- PVT. *See* extrahepatic portal vein obstruction; portal vein thrombosis
- PXR. *See* pregnane X receptor
- pyogenic liver abscess (PLA), 710–12
- pyridoxine, with D-penicillamine therapy, 502–3
- pyrimethamine, 150
- pyrimethamine-sulfadoxine, 369
- pyrrolizidine alkaloids
 hepatotoxicity, 363
 in ICC, 509
- pyruvate carboxylase deficiency, 407–11
- pyruvate metabolism, 631
- Q fever, 718–19
- QIL1 deletions, 634, 639
- quality of life

Shneider

Index

[More J](#)

Index

- in Alagille syndrome, 231–2
post-transplant, 829–30
quantitative LFTs, 101
- RAB27A* mutations, 392
- radiotherapy, for hepatic tumors, 796
- rapamycin, for post-liver transplant AIH, 330
- RDR. *See* relative dose response
- reactivation phase, HBV infection, 291
- Recommended Uniform Screening Panel (RUSP), 415
- rectal varices, portal hypertension, 74–5
- red blood cell abnormalities, neonatal jaundice, 191
- reduced CoQ-cytochrome *c* reductase, 628–30
- reduced-size transplantation (RSLTx), 807–8, 809
- reducing substances test, 403
- regeneration
in ALF, 46
in α_1 -AT deficiency, 430–1
cirrhosis pathophysiology, 59–61
- rejection, liver transplantation
acute, 818
late onset, 826
relative dose response (RDR), 133–6
- renal anomalies. *See also* polycystic kidney disease
in Alagille syndrome, 231
- renal cystic disease. *See* polycystic kidney disease
- renal dysfunction
ALF complications and management, 51
cirrhosis, 63, 69–70
portal hypertension, 80
post-transplant, 828
tyrosinemia, 556–8
Wilson disease, 493
- reovirus 3 infections, neonatal hepatitis, 155
- respiratory chain complexes, 628–30. *See also* mitochondrial hepatopathies
- retinoids, hepatotoxicity, 369
- retinol, for cholestasis, 133–6
- retransplantation, liver, 805, 812, 828
- Rett syndrome, 264
- reverse transcriptase inhibitors, hepatotoxicity, 642
- Reye syndrome
aspirin role in, 359
mitochondrial dysfunction in, 640, 641
- Reye-like hepatotoxicity, valproic acid hepatotoxicity, 371
- Reynoutia multiflora, hepatotoxicity, 364
- rhabdomyosarcoma
clinical presentation, 774, 775
gallbladder, 260
pathology, 777–8
- ribavirin
for HCV infection, 153, 310, 312
for HEV infection, 281
- rickettsial disease, 258, 718
- rifampicin, for pruritus of cholestasis, 119, 125, 236
- rifaximin
in HE, 71
in hepatic encephalopathy, 50
- risperidone, 369
- rituximab, 395
- Rocaltrol, 136–7
- Rocky Mountain spotted fever, 258, 718
- Rotor syndrome
clinical presentation, 200
diagnosis and treatment, 200
laboratory diagnosis, 406
pathophysiology, 200
- RSLTx. *See* reduced-size transplantation
- rubella, 151–2
- RUSP. *See* Recommended Uniform Screening Panel
- SAHA. *See* suberoylanilide hydroxamic acid
- salicylate hepatotoxicity, 359
- Salmonella enteritidis*, 714
- Salmonella paratyphi*, 714
- Salmonella typhi*, 714
- saposins, 570
- sarcoidosis, 743
- sarcoma
gallbladder, 260
hepatic, 780, 790, 791
- SBBO. *See* small bowel bacterial overgrowth
- SBP. *See* spontaneous bacterial peritonitis
- SBS. *See* short bowel syndrome
- SCAD. *See* short-chain acyl-CoA dehydrogenase
- SCD. *See* sickle cell disease
- schistosomiasis, 722, 723
- SCID. *See* severe combined immunodeficiency
- sclerosing cholangitis. *See also* primary sclerosing cholangitis
in critically ill patients, 732
in immunodeficiency, 386, 387
management, 387–8
opportunistic infection in, 384–8
secondary, 342
- sclerotherapy, for portal hypertension, 84, 87–8
- SCO1* deletions, 640
- SCP2, 673–6
- SEC63* mutations, 761–2
- secondary iron overload, 522, 523
- secondary sclerosing cholangitis (SSC), 342
- secondary sclerosing cholangitis in critically ill patients (SSC-CIP), 732
- sedatives, in HE, 71
- seizure
in ALF, 50
Wilson disease, 493
- selective serotonin receptor inhibitors (SSRIs), for Alagille syndrome, 236
- selenium, for cholestasis, 141
- senescence, cholangiocyte, 335
- Sengstaken-Blakemore tube (SSBT), 86
- sepsis
acalculous cholecystitis in, 258
ALF in, 43
cholestasis associated with, 29–30, 246, 730–1
hyperbilirubinemia associated with, 710
in IFALD pathogenesis, 246
in transferase-deficiency galactosemia, 457
- septum transversum (STM), 1, 2
- SERAC1* deletions, 634, 639
- SERPINA1* alleles, 443
- sertraline, for cholestasis, 119
- serum AFP, hepatic tumor diagnosis, 774, 776
- serum aminotransferases. *See* aminotransferases
- serum bile acids, 19–20, 28
- serum bilirubin
Alagille syndrome, 223–4
measurement, 187
- serum copper, Wilson disease, 494
- serum globulins, 101–2
- serum glutamic oxaloacetate transaminase. *See* aspartate aminotransferase
- serum glutamic pyruvic transaminase. *See* alanine aminotransferase
- severe combined immunodeficiency (SCID), 384, 385, 388
- SGOT. *See* aspartate aminotransferase
- SGPT. *See* alanine aminotransferase
- short bowel syndrome (SBS), liver disease with, 242
clinical presentation and natural history, 242–3
liver histology, 243–4
risk factors and pathogenesis, 244–9
treatment, 250–2
- short-chain acyl-CoA dehydrogenase (SCAD), 615, 619
- short-chain enoyl-CoA hydratase, 616
- short-chain ketoacyl-CoA thiolase, 617
- SHP. *See* small heterodimer partner
- sialidosis, 582–3
- sickle cell disease (SCD), 263, 270
- silent gallstones, 263–4, 267–8, 270
- Simpson-Golabi-Behmel syndrome, 770
- simtuzumab, for PSC, 342
- sincalide, for cholestasis, 122
- sinusoidal obstruction syndrome. *See* veno-occlusive disease
- Sjögren syndrome
gallbladder hydrops in, 257
hepatic involvement in, 740
- skeletal symptoms
Alagille syndrome, 227–9
Wilson disease, 494
- skin pigmentation, Wilson disease, 494
- SLC10A1* gene, 26–7
- SLC10A2* gene, 26–7, 267
- SLC27A2*, 676
- SLC30A10* mutations, 511
- SLC33A1* mutations, 511–12
- SLC37A4* mutations, 472
- SLC51B* gene, 29
- SLE. *See* systemic lupus erythematosus
- SLTx. *See* split-liver transplantation
- sludge, gallbladder, 23, 263–4
- SMA. *See* smooth muscle antibody
- small bowel bacterial overgrowth (SBBO), 246
- small cell undifferentiated HB, 777–8, 782
- small for size graft syndrome, 817
- small heterodimer partner (SHP), 22–3
- SMOFlipid, 250–1
- smoking
in α_1 -AT deficiency, 417–18, 420–1, 431–3
protection against PSC, 334
- smooth muscle antibody (SMA), in ALF, 40
- SOD2* mutations, 657
- sofosbuvir. *See* ledipasvir-sofosbuvir
- solitary non-parasitic cysts, liver, 750, 751
- somatostatin, for variceal hemorrhage, 85
- SOS. *See* veno-occlusive disease
- SOX4, in cholangiocyte differentiation, 5
- SOX9, 4
in cholangiocyte differentiation, 5
in intrahepatic bile duct development, 9

Shneider

Index

[More In](#)

Index

- soybean oil-based lipid emulsions, in IFALD, 247–9, 250–1
- specification, hepatic, 1–3
BMP induction, 3–4
endothelial cell signaling, 4–5
FGF induction, 3
- sphingolipidoses, 570
acid sphingomyelinase deficiency, 576–8
Farber disease, 578
Gaucher disease, 570–6
G_{M1}-gangliosidosis, 578–9
Niemann–Pick disease type C, 579–81
- sphingolipids, 570
- spiramycin, for toxoplasmosis, 150
- spironolactone
amenorrhea with, 142–3
for ascites, 68
- splanchnic vasoconstriction, 730
- spleen stiffness, 82–3
- splenomegaly
Alagille syndrome, 222–3
portal hypertension, 74–5, 79
- splenoportal shunting, for portal hypertension in CF, 450–1
- split-liver transplantation (SLTx), 807–8, 809, 810–11
- spontaneous bacterial peritonitis (SBP), cirrhosis, 63, 68–9
- SRT. *See* substrate reduction therapy
- SSBT. *See* Sengstaken–Blakemore tube
- SSC. *See* secondary sclerosing cholangitis
- SSC-CIP. *See* secondary sclerosing cholangitis in critically ill patients
- SSRIs. *See* selective serotonin receptor inhibitors
- staphylococcal infection
neonatal hepatitis, 149
toxic shock syndrome, 715
- statins
hepatotoxicity, 369
for hyperlipidemia and xanthomas in cholestasis, 129
- stavudine, 642
- steatohepatitis. *See* non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
- steatorrhea
in Alagille syndrome, 231
in cholestasis, 129–30
- steatosis
in ALF, 47
in CF, 442, 444, 445, 449
ethanol hepatotoxicity, 641–2
in IFALD, 243–4, 247
NAFLD/NASH, 653
reverse transcriptase inhibitor hepatotoxicity, 642
- Wilson disease, 491
- stellate cells, in CF, 442
- stem cell transplantation. *See* allogeneic stem cell transplantation; hematopoietic stem cell transplantation
- steroids. *See* corticosteroid therapy
- sterol 27-hydroxylase (CYP27A1) deficiency, 603
- STM. *See* septum transversum
- streptococcal infection
group A β -hemolytic streptococci, 715
toxic shock syndrome, 715
Streptococcus pneumoniae, 715
Streptococcus viridans, 258
- stroke, Alagille syndrome, 226–7
- stromal-epithelial tumor
clinical presentation, 774, 775
pathology, 779–80, 788
- suberoylanilide hydroxamic acid (SAHA), for α_1 -AT deficiency, 432–3
- substrate reduction therapy (SRT), for Gaucher disease, 576
- succinate-CoQ reductase, 628–30
- succinylacetone, 548–9, 550–1
SUCLG1 deletions, 634, 638
sucralfate, for cholestasis, 119
- sulfadiazine, for toxoplasmosis, 150
- sulfadoxine. *See* pyrimethamine-sulfadoxine
- sulfamethoxazole. *See* trimethoprim-sulfamethoxazole
- sulfanilamide, 369
- sulfites, urine, 403
- sulfonamides
hepatotoxicity, 369
neonatal jaundice with, 192
- sulfotransferases (SULTs), 349–51
in early development, 18
- sulindac, 367
- SULTs. *See* sulfotransferases
- sunflower cataract, 490–1
- superoxide dismutase, 350
- superoxides, in mitochondria, 629–30
- surgical exploration, for biliary atresia, 170, 172
- Synkavite (vitamin K), 139–40
- syphilis, 717
neonatal hepatitis, 149
- systemic circulation. *See* circulation
- systemic disease, 730
ALF etiology, 43
allogeneic stem cell transplantation, 736
GVHD after, 738–9
liver disease prior to, 736
- other hepatic complications, 739
VOD after, 736, 737–8
- amyloidosis, 743
- collagen vascular disease, 739
Behçet disease, 740
dermatomyositis, 740
JIA, 739–40
Kawasaki disease, 256–7, 741
mixed connective tissue disease, 740
Sjögren syndrome, 257, 740
SLE, 740
systemic sclerosis, 740
- endocrine disorders
adrenal, 741
diabetes mellitus, 192, 260, 494, 655, 656, 741–2
hypopituitarism, 192, 741
thyroid, 741
- heart, 732–3
- hematologic disorders
coagulation disorders, 735
hemoglobinopathies, 734–5
leukemia and lymphoma, 735–6
- hepatic dysfunction in intensive care unit, 730
- hepatic venous outflow obstruction, 733–4
- hypoxic hepatitis, 731–2
- nutritional disorders, 742
celiac disease, 742
dietary supplements, 363–4, 742–3
malnutrition, 64, 71–2, 129–30, 231, 237, 742
NAFLD/NASH as, 657
- sarcoidosis, 743
- secondary sclerosing cholangitis in, 732
- sepsis-associated cholestasis, 29–30, 246, 730–1
- telomere biology disorders, 743–4
- systemic lupus erythematosus (SLE), 740
- systemic sclerosis, 740
- T lymphocyte homing, in PSC, 334–5
- TACE. *See* transcatheter arterial chemoembolization
- tacrolimus
for AIH, 328–9
for post-liver transplant AIH, 330
post-transplant, 817–18
- taurine deficiency, 247
- taurine metabolism, 15
- TBX3, in hepatocyte differentiation, 5
- TCA cycle, mitochondrial functions and, 629–31
- T-cells, hepatic immunology, 45
- TE. *See* transient elastography
- technetium cholescintigraphy, acalculous cholecystitis, 259
- telbivudine, 297
- telithromycin, 361–2
- telomerase, in HB, 787
- telomere biology disorders, 743–4
- tenofovir disoproxil fumarate, 153, 297
- teratoid HB, 777, 784
- terlipressin, for variceal hemorrhage, 85
- TERT* gene, in HB, 787
- tetracyclines
autoimmune-like hepatitis with, 324, 351–2
hepatotoxicity, 366
- tetralogy of Fallot (TOF), in Alagille syndrome, 225–6, 235
- TFEB, gene therapy with, 432
- TFP. *See* trifunctional protein
- TFR2. *See* transferrin receptor 2
- TGR5* mutations, 335
- TGR5* receptor, in cholestasis pathogenesis, 28–9
- THBS2* mutations, in Alagille syndrome, 235
- THCA-CoA oxidase deficiency, 604
- theophylline, hepatic metabolism, 350
- therapeutic vaccines, for HBV infection, 297
- thiazide diuretics, for ascites, 68
- 6-thioguanine, 358–9
- thymidine phosphorylase deficiency, 634, 637–8
- thyroid disorders, 741
- tight junction protein 2 (TJP2) deficiency, 217
- tight junctions, in cholestasis pathogenesis, 31
- timolol, for portal hypertension, 84
- TIPS. *See* transjugular intrahepatic portosystemic shunt placement
- TJP2 deficiency. *See* tight junction protein 2 deficiency
- TLRs. *See* toll-like receptors
- TMEM199-CDG, 478
- tocopherols, for cholestasis, 137–9
d- α -tocopheryl polyethylene glycol succinate (vitamin E, TPGS)
vitamin A with, 134–6
vitamin E supplementation, 139
- tocotrienols, for cholestasis, 137–9
- TOF. *See* tetralogy of Fallot
- toll-like receptors (TLRs), agonists, 297
- tolvaptan, 759–60

Shneider

Index

[More I](#)

Index

- torsion, gallbladder, 256
total parenteral nutrition (TPN)
 black pigment gallstones
 associated with, 263–4
 cholestasis associated with,
 242, 243–4
 fatty acid role in, 247–9
 pathogenesis, 30
 UDCA therapy, 121
total serum bilirubin
 Alagille syndrome, 223–4
 measurement, 187
toxicemic jaundice, 29–30, 246,
 730–1
toxic bile acids, in CF, 442
toxic exposure, biliary atresia
 cause and pathogenesis,
 167–8
toxic metabolites, drug, 350,
 352–3, 370, 371. *See also*
 drug-induced liver
 disease
toxic shock syndrome, 715
toxocariasis, 721–2
toxoplasmosis, 150
TPGS. *See d*- α -tocopheryl poly-
 ethylene glycol succinate
 (vitamin E)
TPN. *See* total parenteral
 nutrition
transaminases. *See*
 aminotransferases
transcatheter arterial
 chemoembolization
 (TACE), for hepatic
 tumors, 795–6
transcriptomic analysis,
 hepatoblast
 differentiation, 5–7
transferase-deficiency
 galactosemia, 455, 457,
 468
 biochemical features and
 pathogenesis of toxicity,
 458–9
 clinical presentation, 457–8
 diagnosis, 459
 genetics, 460
 laboratory findings, 458
 molecular basis of, 457
 pathology, 459
 prognosis, 461
 screening, 457, 460
 treatment, 460–1
transferrin, 515
transferrin glycoform analysis,
 475–6
transferrin receptor 2 (TFR2),
 516, 517
transferrin saturation, 519, 520
transforming growth
 factor-alpha, in HB,
 786–7
transforming growth factor-beta,
 intrahepatic bile duct
 development, 8–9
transfusional iron overload, 522,
 523
transfusion-transmitted virus
 (TTV), 154
transient elastography (TE)
 CF-associated liver disease,
 448, 449
 cirrhosis, 60
 fibrosis, 244
 IFALD, 244
 methotrexate treatment
 monitoring, 366
 NAFLD/NASH, 660–1
transient gallbladder distension,
 257–8
transient neonatal tyrosinemia,
 14
transient tyrosinemia, 552
transjugular intrahepatic
 portosystemic shunt
 placement (TIPS)
 for ascites, 68
 for portal hypertension, 86–7
transjugular portosystemic
 shunt, for portal
 hypertension in CF,
 450–1
transplacental infection, 147
transplant evaluation, 801–2
transplantation. *See* hematopoie-
 tic stem cell transplanta-
 tion; liver transplantation
transporters, hepatic
 in bile formation and flow,
 26–7, 28
 in early development, 21–2
transulfuration pathway, in early
 development, 15
tremelimumab, 359
Treponema pallidum, 149, 717
Trichosporon cutaneum, 725
triethylene tetramine
 dihydrochloride
 (trientine)
 in pregnancy, 506–7
 for Wilson disease, 501–2, 503,
 504, 506–7
trifunctional protein (TFP), 615,
 616
triheptanoate, 623–4
trimethoprim-sulfamethoxazole,
 369
triple gallbladder, 256
trisomy 17–18 syndrome,
 neonatal hepatitis, 156–7
trisomy 21 (Down syndrome)
 gallbladder motility in, 260
 neonatal hepatitis, 156–7, 524
TRMU deletions, 634, 639
tryptophanyl-tRNA synthetase
 deficiency, 639–40
TSM deletions, 640
TTV. *See* transfusion-trans-
 mitted virus
tuberculosis, 149, 715–16
TUFM deletions, 640
tularemia, 715
tumors of liver, 769. *See also*
 hepatoblastoma; hepato-
 cellular carcinoma
acquired genetic abnormalities
 in, 791
 HB, 782–7, 793
 HCA, 788–90
 HCC, 787–8
 mesenchymal hamartoma
 and embryonal sarcoma,
 790
 vascular tumors, 790
classification, 780
clinical presentation, 769, 774,
 775
constitutional genetic and
 metabolic abnormalities,
 770–4
diagnosis
 AFP, 774, 776
 imaging, 774, 775, 776
drug-induced, 351
epidemiology, 769–70
etiology, 770, 771
future research prospects, 796
gallbladder, 260
liquid biopsy of, 796
pathology
 cholangiocarcinoma, 779
 errors in, 782
 HB, 776–9, 781, 782, 784,
 785, 786, 791
 HCA, 776–7, 781–2
 HCC, 776–7, 778–9, 786,
 787
 hemangioendotheliomas,
 776–7
 hemangiomas, 776–7
 mesenchymal hamartomas,
 780–1, 792
 MRT, 777–8
 NSET, 779–80, 788
 rhabdomyosarcoma, 777–8
in PFIC2, 209, 210, 212
prognostic considerations,
 791–2, 794
staging, 775–6, 777,
 778, 779
surveillance for, 796
treatment, 793
 chemotherapy, 795
 liver transplantation, 795,
 804–5
 microwave ablation therapy
 with chemoembolization,
 796
 multidrug resistance in, 796
 radiotherapy, 796
 surgery, 793–4
 TACE, 795–6
 in tyrosinemia, 565
tussilago, 363
Twinrix, 276–7
TWNK deletions, 634, 638
TYMP deletions, 634, 637–8
typhoid fever
 acalculous cholecystitis in, 258
 hepatitis, 714
tyrosine, 551
tyrosinemia
 in ALF, 41–2
 clinical categories of, 548
 diagnosis of, 551–2
 differential diagnosis for, 552
 gene therapy for, 566
 genetics of, 549–50
 hepatocyte transplantation
 for, 566
 imaging in
 kidney, 558
 liver, 558
 pancreas, 558
 inborn error of metabolism,
 548
 liver transplantation, 553–4,
 563, 564–5, 566, 803
 liver tumors, 565
 management of
 diagnostic samples for, 560
 diet therapy, 560–2
 monitoring of, 561, 562
 molecular diagnosis, 551
 newborn screening for, 550–1
 nitisinone treatment for, 803
 complications and
 questions in, 563–4
 corneal crystals, 563
 developmental outcome
 with, 563
 diet and, 561
 initiation of, 562
 liver and kidney and, 553,
 562–3
 non-adherence to, 564
 suboptimal nutrition and
 obesity, 563–4
 non-nitisinone-treated
 patients
 cardiomyopathy, 558
 hypoglycemia, 558
 liver, 552–4, 555
 neurologic crises, 554–6
 renal disease, 556–8
 pathology of
 heart, 560
 kidneys, 559–60
 liver, 555, 558–9
 pancreas, 560
 peripheral nerve, 560
 pathophysiology of, 548–9
 pregnancy and, 562
 prenatal diagnosis for, 552
 remaining challenges with,
 566–7
 transient neonatal, 14
 treatment issues
 acute liver crises, 564
 chronic liver disease, 564–5
 for kidney, 565–6
 liver tumors, 565
 neurologic crises, 565
tyrosinemia type 1. *See* heredi-
 tary tyrosinemia type 1
tyrosinemia type II, 552
tyrosinemia type III, 552
ubiquinone, for mitochondrial
 hepatopathies, 646, 647
UC. *See* ulcerative colitis

Shneider

Index

[More In](#)

Index

- UCD. *See* urea cycle disorders
- UCDA. *See* ursodeoxycholic acid
- UDP-galactose-4-epimerase, 455–7. *See also* epimerase-deficiency galactosemia
- UDP-glucuronosyltransferases, 349–51
- UGT1A1* mutations, 657
- UGT1A* mutations
in Crigler–Najjar syndrome, 198–9
in gallstone formation, 267
Gilbert syndrome, 195–6, 197
- UGT enzymes, in early development, 18
- ulcerative colitis (UC), PSC with, 333, 334, 336, 339–40
- ultrasonography
acalculous cholecystitis, 259
CF-associated liver disease, 447–8
CHF, 754
gallbladder hydrops after, 257–8
gallbladder tumors, 260
gallstones, 268
graft dysfunction, 822
hepatic tumors in, 774
neonatal cholestasis, 112
portal hypertension, 82
- ultraviolet light, for cholestasis, 119, 127
- UNC45A* mutations, 217
- unconjugated bilirubin
measurement, 187
in pigment gallstones, 262–3
- unconjugated hyperbilirubinemia
bilirubin metabolism disorders, 196
neonatal cholestasis, 109–10
- undifferentiated sarcoma, hepatic, 780, 790, 791
- universal vaccination
HAV, 277–8
HBV, 298
current programs for, 298
effectiveness in infection prevention, 299
long-term immunogenicity and need for booster doses, 299
problems with current program, 299–300
reduction of HCC, 299
reduction of mortality in fulminant infection, 299
WHO recommendation for, 298
- unsaturated fatty acids, 617
- urea cycle
function of, 698
molecular aspects of, 699
- urea cycle disorders (UCD)
in ALF, 41–2
clinical presentation of, 699–700
delayed onset of, 701
diagnosis of, 702–4
differential diagnosis of, 704
future directions for, 707
imaging for, 707
incidence of, 698
laboratory diagnosis, 413–14
liver transplantation, 802–3
management of
diagnosis for, 706
in hyperammonemic coma, 704–5
long-term, 706–7
osmotic agents, 706
pharmacologic, 705–6
neonatal onset of, 700
single enzyme deficiencies, 701–2
sources of, 699
transporter defects, 702
- urea synthesis, 15
- uridine inhibitors, 460–1
- urinary tract infections, 149
- urine samples, IEM, 403, 413
- urine tests
amino acids, 102
copper, 494–6
IEM, 402–3
urobilinogen, 100
- URO-decarboxylase, 531–2, 539, 540, 544
- URO-synthase, 531, 542, 544
- ursodeoxycholic acid (UCDA)
for AIH-PSC overlap syndrome, 329
for CF-associated liver disease, 449–50, 451–2
in CHF, 755
for cholestasis, 118–20, 121
Alagille syndrome, 120, 236
bile acid synthesis defects, 121
biliary atresia, 121
CF, 120
hepatic sinusoidal obstruction syndrome and graft-versus-host disease, 121
hyperlipidemia and xanthomas, 128–9
PFIC, 120
primary sclerosing cholangitis, 120
pruritus, 126
TPN-associated, 121
for cholesterol gallstones, 269
for HIV cholangiopathy, 389–90
for IFALD, 251
for PSC, 340–1
for sclerosing cholangitis in immunodeficiency, 388
- vaccination. *See* immunization
- valganciclovir, 150
- valproic acid
hepatotoxicity
in ALF, 39
in Alpers syndrome, 371–2
clinical presentation, 370, 371
investigations, 370–1
mitochondrial dysfunction, 371, 641, 646
serum carnitine in, 372
toxic metabolites, 370, 371
- van den Bergh test, 187
- vancomycin
in HE, 71
for PSC, 341
- VAP-1. *See* vascular adhesion protein-1
- VAQTA, 276–7
adverse effects, 277
efficacy, 277
long term immunogenicity, 277
recommendations, 277–8
- variceal band ligation (VBL), 84, 87–8. *See also* band ligation therapy
- variceal hemorrhage, 79, 83–4
emergency therapy, 84–5
endoscopic, 86
mechanical, 86
pharmacologic, 85
surgical and interventional radiologic, 86–7
pre-primary prophylaxis, 84
primary prophylaxis, 84
screening, 89–90
secondary prophylaxis, 87–9
- varicella-zoster virus (VZV)
ALF in, 42–3
neonatal hepatitis, 156
- variegate porphyria (VP), 533
clinical features of, 541
diagnosis of, 541
homozygous dominant, 541–2
prevalence of, 541
treatment of, 541
- vascular adhesion protein-1 (VAP-1), 334–5
- vascular anomalies
Alagille syndrome, 226–7
biliary atresia, 168
hemangioendotheliomas, 776–7
- vascular endothelial growth factor receptor 2 (VEGFR2), 4–5
- vascular injury, in ALF, 45–6
- vascular resistance, in portal hypertension, 76–8
- vascular tumors
angiosarcomas, 780, 790
EHes, 780, 789, 790
hemangiomas
acquired genetic abnormalities in, 790
AFP levels, 774
clinical presentation, 774, 775
pathology, 776–7, 780, 789
surgical removal of, 793–4
- vasoconstrictors, for HRS, 70
- vasodilation, portal hypertension, 78–9
- vasopressin/vasopressin analogues
for HRS, 70
for variceal hemorrhage, 85
- vasopressors, hepatic dysfunction with, 730
- VBL. *See* variceal band ligation
- vedolizumab, 341–2
- VEGFR2. *See* vascular endothelial growth factor receptor 2
- Veillonella*, 334
- veno-occlusive disease (VOD), 351
anti-neoplastic agents, 358–9
hepatic venous outflow obstruction, 733–4
herbal medications, 363
after stem cell transplantation compounds associated with, 736, 737
diagnosis, 737
incidence, 737
treatment of, 737–8
- venous outflow obstruction, after liver transplantation, 824–5
- ventral midline of endoderm lip (VMEL), 1, 2
- vertebral anomalies, Alagille syndrome, 227–9
- very-long-chain acyl-CoA dehydrogenase (VLCAD), 614, 618
- vinca alkaloids, 358–9
- vincristine, 795
- viral hepatitis. *See also specific hepatitis virus infections*
in immunodeficiency, 388–9
neonatal
CMV, 150
enterovirus, 154–5
HAV, 152
HBV, 152–3
HCV, 153
HDV, 153–4
herpes simplex, 151
HEV, 154
HGV, 154
HHV-6, 155
HIV, 155–6
paramyxovirus, 155
parvovirus B19, 155
reovirus 3, 155
rubella, 151–2
TTV, 154
VZV, 156
Zika, 156
- viral infections
acalculous cholecystitis in, 258
ALF in, 42–3
biliary atresia cause and pathogenesis, 165
gallbladder hydrops in, 257

Shneider

Index

[More I](#)

Index

- post-transplant
early, 820–1
in long-term follow-up, 821
patient evaluation, 821
postoperative management,
816–17
- visceral larva migrans, 721–2
- vitamin A
for cholestasis, 133–6
hepatotoxicity, 369
- vitamin B, 624
- vitamin D, 133, 136–7
- vitamin E
for cholestasis, 133, 137–9
for hydrophobic bile acid
hepatotoxicity, 642
for ICT, 511
for NAFLD/NASH, 666–7
for Wilson disease, 503, 505
- vitamin K
for cholestasis, 133, 139–40
tests for, 98–9
- vitamins
fat-soluble
for Alagille syndrome, 237
bile acid synthesis defects
and, 598, 599
for cholestasis, 133–40
water-soluble, for cholestasis,
140
- VLCAD. *See* very-long-chain
acyl-CoA dehydrogenase
- VMEL. *See* ventral midline of
endoderm lip
- VOD. *See* veno-occlusive disease
- volatile anesthetic agents, 362–3
- von Meyenburg complexes,
760–1
- VP. *See* variegate porphyria
- VZV. *See* varicella-zoster virus
- waist circumference, NAFLD/
NASH association with,
654–5, 659–60
- waiting list, liver transplantation,
807, 808
- WARS2 deletions, 639–40
- water-soluble vitamins, for
cholestasis, 140
- weight loss, for NAFLD/NASH,
666–8
- WHO. *See* World Health
Organization
- whole organ transplantation,
807–8, 809, 810–11
- willow tree bark, 364
- Wilms tumor, 774, 775,
779–80
- Wilson disease
ALF in, 42, 491, 497, 500
ATP7B mutations in,
484, 485–6, 488,
489, 641
ceruloplasmin in, 486, 489,
494–5, 496
clinical presentations,
488–91
amenorrhea and
gynecomastia, 494
cardiac, 493–4
hematologic, 493
hepatic, 491–2, 497,
498
Kayser–Fleischer ring, 490,
491, 499, 500
neuropsychiatric, 492–3
renal, 493
skeletal, 494
skin pigmentation, 494
sunflower cataract, 490–1
diagnosis, 494, 495
- in asymptomatic siblings,
500–1
diagnostic testing, 499–501,
502
hepatic presentations,
494–9
Leipzig Scoring System, 501,
502
liver histology, 496,
497–9
neuropsychiatric
presentations, 499
epidemiology, 488–9
genetic testing, 496
genetics, 484, 485–6, 488, 489,
641
hepatic tumors in, 492, 771
historical aspects, 488
laboratory diagnosis, 406
laboratory findings, 494
mechanism of copper toxicity
in, 487
mitochondrial dysfunction in,
640–1
pathogenesis, 489
treatment, 501
antioxidant therapy, 503,
505
copper chelation therapy,
501–5, 506–7
gene therapy, 506
liver transplantation, 505–6
in pregnancy, 506–7
before surgery, 507
- Wilson Disease Prognostic
Index, 506
- wingless-related integration site
(WNT) signaling
in HB, 784, 785
in HCC, 787–8
- in hepatic specification, 3
- Wolman disease, 586–7
- World Health Organization
(WHO)
cirrhosis definition, 58
HBV vaccination
recommendations, 298
- xanthomas
Alagille syndrome, 223
cholestasis, 128–9
- xenobiotic metabolism. *See*
hepatic drug metabolism
- xenobiotic NRs, 17
- XIAP protein, 487
- X-linked hyper-IgM syndrome,
324–5
- X-linked lymphoproliferative
(XLP) disease, 393–4
- YAP, in intrahepatic bile duct
development, 9
- Yersinia enterocolitica*, 715
- yolk sac tumors, 774, 775
- zalcitabine, 642
- Zellweger spectrum
disorders. *See* peroxisome
biogenesis disorders-
Zellweger spectrum
disorders
- Zellweger syndrome, 605–6
- zidovudine, 642
- Zika virus, 156
- zinc therapy**
for cholestasis, 141
mechanism of, 484, 491
in pregnancy, 506–7
for Wilson disease, 501–2, 503,
505, 506–7